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ABSTRACT

CLINICAL TRIAL OF COGNITIVE-BEHAVIORAL THERAPY TO REDUCE
ANTIRETROVIRALSIDE EFFECTS IN HIV PATIENTS

By
R. Eric Doerfler
December 2010

Dissertation supervised by Linda Goodfellow, PhD, RN
Antiretroviral therapy (ART) for HIV/AIDS has led to significant improvements
in survival and a reduction in AIDS-related morbidity. Adherence to regimens is vital, yet
clinical observations and research have suggested that side effects are a significant reason
for non-adherence. This randomized, controlled clinical trial was a pilot study sought to
determine if a brief exposure cognitive-behavioral therapy (CBT) could reduce side effect
symptoms in HIV/AIDS patients on ART. Methods: 33 participants were randomized to
standard adherence education alone or adherence education plus three sessions of CBT
over a period of three months. Results: Completing the study were 17 males and one
female; whites, blacks, and Hispanics were represented in the sample. Mean duration of
ART was over 200 weeks. Participants in the experimental group reported significantly
less nausea and fatigue, compared to those in the control group (Mann-Whitney U, p <
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.05). There were no differences in adherence across the study, which was reported at
>94%. No differences in CD4 lymphocyte counts or viral load were observed between
groups over the course of the study. Observations suggested that scheduling visits with
the psychologist delivering the CBT sessions was an obstacle to continued participation.
The use of side effect reducing medication was low in both groups. Increasing daily
practice sessions was correlated with an increase in reported nausea scores. The reason
for this observation is not known. Brief exposure to CBT training in male HIV/AIDS
patients on ART appears to reduce side effect symptoms. A larger sample with more
female representation is warranted to further explore this intervention Referral for CBT to
reduce side effect symptoms in similar patients may be warranted.
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Chapter 1
Statement of the Problem
Introduction
Side effects can occur from the use of any drug. Patients who have human
immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)
related to HIV follow a similar course of treatment similar to that of the cancer patient
undergoing chemotherapy. As with all medicines, antiretroviral treatment (ART) for
HIV/AIDS may result in side effects that limit patients’ ability to continue treatment
Clinically, the researcher has listened to HIV/AIDS patients on ART describe feeling ―toxic‖
or ―sick on the meds.‖
Those with HIV who are on ART may miss medication doses or discontinue the
regimen for various reasons. Reasons for non-adherence include substance abuse,
forgetfulness, scheduling difficulties and lifestyle interference, and misconceptions about the
use of the elements of ART. A significant reason for discontinuation is side effects, including
side effects not responsive or only partially responsive to anti-side effect medications
(Bartlett, 2002; Chesney, 2000, 2003; Laws, Wilson, Bowser, & Kerr, 2000). An anecdotal
observation is that despite treatment with side effect reducing medications (SERM) some
patients’ symptoms grow worse. Patients on ART have made statements such as, ―I know this
is all in my head.‖ Thus, some patients seem to understand that their own mental framing of
ART can influence their experience of side effects. Based on oncology literature the author
referred a few such patients to a cognitive-behavioral therapist for help controlling side
effects and anxiety. The researcher’s request at the time was for the therapist to provide
cognitive-behavioral therapy (CBT) to help those patients reframe the experience of ART and
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to teach them techniques for reducing anxiety and emotional arousal associated with that
experience. In this very small series of patients, two went on to successful ART with
moderated side effects and an improved ability to sustain adherence to their regimens over
time. This clinical anecdotal experience, in addition to studies reported in the oncology and
psychological literature, are the bases for this study.
Questions
The present study examined whether CBT can help to reduce the discomfort of side
effects in ART. It was hypothesized that a reduction of side effects might alter how patients
adhere to their regimens. Finally, it was further hypothesized that if patients adhere better,
there might be changes in serum levels of HIV, and CD4 lymphocyte counts. This led to the
following questions for study:


Will a CBT intervention reduce side effects (nausea, pain, fatigue, and/or anxiety) in
HIV patients undergoing ART compared to patients who only receive education on
proper adherence to medication (standard of care [SOC])?



What is the relationship between measured side effects and self-reported adherence?



What is the relationship between measured side effects and clinical measures (CD4+
lymphocyte [CD4] counts and serum viral burden [―viral load,‖ VL])?

Hypotheses


Participants who receive the CBT intervention will report a reduction in side effects,
compared to participants who only receive the SOC.



Participants who receive the CBT intervention will show a difference in adherence
compared to those who only receive the SOC.
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Participants who receive the CBT intervention will show a difference in CD4 and VL
compared to those who only receive the SOC.

Assumptions Underlying the Research
Methodological assumptions underlying the research were:


Study participants were honest in their symptom reporting, as well as how they felt
mentally and physically.



Participants were able to make reliable estimates of symptom intensity and duration,
and faithfully marked the instruments thus. It was assumed that participants would not
hurry through the questions, nor hastily mark answers in order to ―get through‖ the
questions quickly.



Laboratory data from various laboratories is standardized. A detailed discussion of
laboratory methods and standardization appears in Chapter 3.

Definition of Terms
Adherence. Patients’ ability to continue on a medication or other treatment regimen
is generally subsumed under the rubric of ―compliance‖ or its more recent phrasing
―adherence.‖ Alternative ways of defining compliance recognize patient participation in
clinical decisions, with clinicians serving as expert advisers (Vermeire, Hearnshaw, Van
Royen, & Denekens, 2001), and ―adherence‖ has become popular (Dunbar, 1980; Lieberman,
1996). The terms are often used interchangeably, but adherence is the term of choice among
treatment professionals in HIV disease. Adherence in this study was measured as the
percentage of doses taken, according to the regimen, based on patient recall, recorded on the
VAS and proportion of doses taken in three days, a measurement known as ―three-day
recall‖. The use of VAS in adherence measurement in HIV is discussed under methodology.
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Antiretroviral therapy. Antiretroviral therapy is the use of a minimum of two
antiretroviral drugs with the aim of reducing serum viral nucleic acids below the limits of
detection. Most commonly, at least three agents from at least two different classes of
antiretroviral drugs form the basis for any regimen (Panel_on_Antiretroviral_Guidelines_for_
Adults_and_Adolescents, 2009)
Clinical endpoints. Clinical Endpoints were measured by CD4+ lymphocyte subset
(―CD4 count‖) and serum HIV nucleic acids (―viral load‖) which are the standard measures,
termed clinical endpoints, in HIV/AIDS treatment centers (Fahey et al., 1990). CD4 count
and viral load were measured at two time points, at the beginning and at the end of subject
participation in the study. Only results from samples within 30 days of the beginning of the
study (first measurement) or end of the study (last measurement) were used.
Cognitive-behavioral therapy (CBT). In this study, CBT is defined as a system of
psychological treatment based on the understanding of a patient’s beliefs and thoughts, which
drive their experience. In CBT theory, so-called automatic thinking contributes to discomfort
or psychological distress. In CBT the patient’s thoughts are reframed through discussion and
education. Adjunctive techniques to reduce arousal aid this process. Such techniques include
relaxation, guided imagery, biofeedback, and other methods (A. T. Beck, 1976).
Side effect symptoms. In this study there are two types of symptoms to consider. The
first type of symptom signals some potentially serious problem such as anemia, lactic
acidosis, or peripheral neuropathy. The second type of symptom includes sensations that are
bothersome, but do not necessarily demand a change of regimen or other medical
intervention. Several of the symptoms that this study examined fit into both categories.
Serious problems were ruled out by the usual clinical follow up, just as in normal practice.
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Once serious problems were ruled out, what remained were the persistent, troublesome,
wearying symptoms that were the focus of this study: nausea, fatigue, pain, and anxiety. The
terms discomfort and comfort are defined as the presence or absence of those four symptoms,
and are also related to the domain scores of the Short Form-36 (SF-36).
Nausea. Nausea is defined as an unpleasant sensation localized to the abdomen. In
vernacular terms it is also described as ―queasiness,‖ or being ―sick in the stomach‖ (NCCN,
2005). The perception of duration of nausea, its average perceived intensity, and its greatest
perceived intensity were measured by VAS at four time points.
Pain. In this study, pain is unpleasant sensation rooted in nociception that may or may
not be related to tissue damage (Joffe & Sandler, 1967; Merskey & Spear, 1967). Pain may
be malignant or non-malignant, and other than ruling out life threatening causes, the cause of
the pain was not considered. The perception of duration of pain, its average perceived
intensity, and its greatest perceived intensity were measured by VAS at four time points.
Pain over the last four weeks was also be measured by verbal intensity scaling (Item 7) in the
Short Form-36, at four time points.
Fatigue. Hart, Freel, and Milde (1990) defined fatigue as ―a subjective self-evaluation
of sensations associated with discomfort, decreased motor and mental skill and increased task
aversion‖ (pp.967-968). Tack (1990), looking at fatigue reported by rheumatoid arthritis
patients described it as, ―the subjective sensation of generalised tiredness or exhaustion‖ (p.
154). The perception of duration of fatigue, its average perceived intensity, and its greatest
perceived intensity was measured by VAS at four time points. Role performance (RP),
physical functioning (PF), and vitality, terms operationalized in the SF-36, was also measured
as behaviors (RP and PF) and sensation (vitality) related to fatigue, at four time points.
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Anxiety. Whitney (1992) defined anxiety by four critical attributes.


There is the presence of a vague, uneasy feeling of discomfort or dread.



The source or cause of the anxiety is unknown or nonspecific in origin.



Subjective responses that act as energizers (i.e., prompt action) but cannot be
observed directly are present; these responses may be classified as
psychological/behavioral.



Objective signs that are the result of the transformation of the energy into
relief behaviors are present; these signs may be classified as physiologic,
psychological/behavioral, or cognitive.

The perception of duration of anxiety, its average perceived intensity, and its greatest
perceived intensity was measured by VAS at four time points. Role-emotional (RE), social
functioning (SF), and mental health (MH), terms operationalized in the SF-36, were also
measured as related to anxiety, at four time points. However, domains such as MH also
include measurement of items related to depression and other aspects of mood. This is
considered further in Chapter 5.
Theoretical Framework
The theoretical framework for this study was based on cognitive control of autonomic
responses. Skinner (1971) suggested the use of consequences to modify behavior (operant
conditioning), but Pavlov’s original work dealt with classical, also called respondent,
conditioning. Respondent conditioning is reflexive, intimately coordinated with the
sympathetic and parasympathetic branches and endocrine function, and targets physical
responses operated by those systems, chiefly as a means of ensuring that organisms adapt to
their environment (Rescorla, 2003). Pavlov’s classic example was based on the fact that the
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presentation of food leads to saliva production. The dog in Pavlov’s experiment was given
food when a bell was rung. The stimulus of the bell was paired with the stimulus of being
given food, and an autonomic response was generated.
Anticipatory nausea and vomiting (ANV) in antineoplastic therapy is one example
from oncology that exemplifies how conditioning combined with autonomic arousal
potentiates symptom experience. The nausea and vomiting that may have occurred from a
first chemotherapy treatment form a stimulus-response pair. The circumstances of the event
become paired with nausea and vomiting and may elicit the autonomic response without
actual antineoplastic therapy being administered. A similar-appearing process has been
observed by the author to occur in patients on ART. In their theoretical analysis of ANV,
Burish and Carey (1986) noted that there are several theories about how this problem
develops. Proposed alternative theories with, they argue, less supporting evidence are 1)
psychodynamic readjustment to serious illness, 2) attention-seeking behavior, and 3) anxietyinduced nausea related to as-yet-poorly understood mechanisms in brain and gut tissue.
Respondent conditioning is essentially classical conditioning, but Burish and Carey note that
even this generally-accepted theory fails to explain why some people develop conditioned
responses and others do not, nor why varying numbers of exposures to adverse symptoms
lead to the conditioned responses in different patients (lending some credence to the
possibility of alternate explanations). The authors posit an extension of the respondent
conditioning theory, that such conditioning is mediated by anxiety.
In this way, the theory selection for this project admits that ART may be a desired
option, indeed may be understood as necessary and life-saving by the patient. However, the
emotional reaction to that experience may change patient reactions even though he/she knows
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such reactions may reduce his or her ability to maintain the treatment. Thus, the theory
suggests that strategies to reduce anxiety as well as change automatic thinking would be
beneficial.
Burish and Carey (1986) propose that anxiety is a key mediating factor in somatic
symptoms such as ANV and other complaints. From the theoretical perspective in this study,
CBT offers a means to address several factors at once.
Cognitive-behavioral therapy proposes that life challenges may be engaged by
discovering the complaint (e.g., ―I’m anxious about taking my meds.‖) and then to determine
what maladaptive automatic thinking drives that emotional sensation (A. T. Beck, 1976; J. S.
Beck, 1995). The goal of CBT is to engage higher cortical function to change the automatic
thinking, which relieves the emotional sensation. Behavioral techniques serve to gain
autonomic control (which can also serve to shift the locus of control inward), which in turn
makes it easier for the patient to assert control over automatic thinking (A. T. Beck, 1976; J.
S. Beck, 1995; Kalichman, 1995).
Significance to Nursing
Schietinger and Daniels (1996) interviewed HIV/AIDS patients on their perceptions
regarding their health care, and in particular, how they view their health care providers. Of
the five themes that emerged, one pertinent to the aim of this study is that patients wanted
their providers to appreciate them holistically, that is with a sense of the importance of their
psychosocial and spiritual needs, as well as the physical needs. Nurses assess patients for
potential problems with side effects and adherence (Spirig, Moody, Battegay, & DeGeest,
2005; Wolfe, 1997). Taking a diagnostic approach (Caetano & Pagliuca, 2006), HIV/AIDS
patients who undertake ART are at risk for the diagnoses in Table 1.1

8

Table 1.1
Common Nursing Diagnoses Applicable to Patients on ART
________________________________________________________________________
Acute pain
Ineffective therapeutic regimen management
Activity alteration
Activity intolerance/risk
Anxiety
Body nutrition deficit/risk (related to nausea/vomiting)
Chronic pain
Fatigue
Fluid volume deficit/risk
Instrumental Activities of Daily Living (IADLs) alteration
Knowledge deficit of therapeutic regimen
Nausea
Sleep pattern disturbance
Swallowing impairment (related to anxiety, with impact on dose consumption)
Unspecified pain

________________________________________________________________________
The diagnoses in the Table focus on problems related to ART. The Table also does
not include diagnoses that are unlikely to respond to cognitive-behavioral interventions as
designed in this study (e.g., progressive muscle relaxation, guided imagery), such as diarrhea
and/or bowel incontinence, blood pressure alteration and/or respiration alteration. Examples
of this include anemia due to non-nucleoside reverse transcriptase inhibitors (NRTIs),
contraceptive risk related to pregnancy that may occur during occurring during use of
efavirenz [Sustiva®, Bristol-Myers Squibb, New York]), or tactile alteration from sensory
loss related to neurotoxic agents such as stauvudine [Zerit®, Bristol-Myers Squibb, New
York]).
Pharmacologic therapy of HIV/AIDS has become the mainstay of medical treatment.
Nursing complements such treatment in several ways. This study concerned itself with a
possible method nurses may use to complement medical therapy, by helping patients remain
adherent through the employment of a method which may reduce side effect burden.
9

Summary
This study was a randomized, controlled clinical trial that compared the use
CBT/SOC to SOC alone in an attempt to reduce side effect symptoms in HIV/AIDS patients
on ART. The study also sought to explore whether symptom reductions led to improvements
in adherence to medical regimens, and further, to greater improvements in CD4 counts and
viral loads, compared to controls. Standard of care was defined as adherence education and
side effect monitoring, as currently practiced. Nausea, pain, fatigue, and anxiety as measured
by VAS at four time points in this multiple measures study, were the main dependent
variables. Anxiety may potentiate the other three symptoms, as well as serve as a source of
discomfort itself. The theoretical framework of the study is based on cognitive control of
autonomic responses. Theory suggests that symptoms such as the four selected for this study
would respond to a reduction in autonomic arousal. Cognitive therapy and behavioral
techniques are one means by which patients may access control of arousal, thus leading to a
perceived reduction of the symptoms under study, and the use of CBT was the independent
variable in the study. Nurses diagnose the symptoms suffered by HIV/AIDS patients on ART
and intervene to reduce those symptoms. The study explored the utility of a method by which
nurses may improve the care and comfort of their patients.
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Chapter 2
Review of the Literature
The Three Historical Periods of HIV Management
Clinical HIV disease was detected when several homosexual men, who had no known
cause of immunodeficiency, were treated for pneumonia caused by Pneumocystis carinii
(now P. jirovecii), an opportunistic pathogen that only causes disease in the
immunosuppressed, in 1981; two died (CDC_MMWR, 1981). From the beginning an
epidemiological pattern suggested an infectious cause was among the hypotheses for this
acquired immunodeficiency, although there were also many competing hypotheses including
immunodeficiency induced by abused inhalants such as amyl nitrite, or autoimmunity
stemming from exposure to spermatozoa. By 1985 the cause of AIDS was elucidated at about
the same moment in both France and the United States (Sepkowitz, 2001). Disease-causing
retroviruses were not entirely new. The observation that certain RNA viruses (in which the
genome is carried in riboxynucleic acid, analogous to a photographic ―negative‖) copied their
genetic information into host-cell DNA (deoxyribonucleic acid) changed the way biologists
had always thought about the direction of genetic information transfer (classically, from
DNA to RNA to protein) (Fauci & Longo, 2001). Since then HIV has infected tens of
millions throughout the world (Sepkowitz, 2001; UNAIDS, 2006). During the more than 20
years of the AIDS epidemic, there have been three phases. The first, from 1981 to 1985,
involved elucidating the cause. The second, from 1985 to 1996, was a period in which all
attempts at therapeutic success against the virus led to failure, and the infection was
considered fatal. The third period is from 1996 to today, the age of effective combination
ART. However, this has not led to the hoped-for ―cure‖ of HIV infection per se. In the next
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sections, this and related issues will be discussed in terms of the life cycle of HIV, its affinity
for key immune system component cell types, its viral dynamics and genetic instability, why
treatment must endure for long periods of time, and how viral genetics may lead to drug
resistance when patients are unable to adhere to the regimens properly.
Immunobiology of HIV
Retrovirus Genetics and the Persistence of HIV Infection. As suggested above,
retroviruses become a part of the host cell genome. Thus, elimination of an HIV infection
must also eliminate every infected cell in the host. A detailed discussion of the gene
sequences in retroviruses is beyond the scope of this paper, but it is important to note one
feature. This involves the first step in the productive infection of host cells by retroviruses, as
well as the formation of antigen-specific immune competence.
Normal Human Immune Responses. Cluster of differentiation (CD) is a set of over
250 cell surface antigens that act as receptors, ligands, and perform other tasks. The fourth in
the series, CD4, is a 55 kiloDalton protein chain occurring on certain thymocytes,
macrophages, and lymphocytes. Major histocompatability complex (MHC; types I and II) on
host cells contains a small sample of viral peptide which has been derived from within the
infected host cell to form a supercomplex that comes into contact with a T-cell receptor
(TCR). The signal that results from this sequence of events triggers the CD4 lymphocyte to
activate macrophage killing of bacteria, and B-lymphocytes to differentiate and produce
antigen-specific immunoglobulins. Macrophages are a major cell subset in immunity to
bacterial infection. Immunoglobulins help to provide immunity to viral infections and to
neutralize bacterial and other toxins (Janeway, Travers, Walport, & Shlomchik, 2005).
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Retroviruses Downregulate Normal Human Immunity. The lentivirus family of
retroviruses, and especially HIV, contain a coding sequence, nef (negative-regulation factor),
which downregulates CD4, and since this is a key component of the MHC/TCR complex and
serves as the cellular receptor for HIV, T-lymphocyte activation pathways are altered,
affecting immune system function downstream (Fauci & Longo, 2001; Janeway, et al., 2005).
HIV. An encapsulated virus approximately 100nm in diameter, HIV contains a 9.7
kilobase (kb) genome consisting of three major structural genes, including the reverse
transcriptase (RT) gene—the gene that makes a retrovirus what it is, enabling HIV to ―write
itself into‖ the genes of host cells for which it is tropic (Streicher, Reitz, & Gallo, 2000).
The virus fuses with the host cell via the gp120/gp41 complex on its lipid membrane;
the complex itself binds with CD4. For entry, the virus uses one of two co-receptors located
on cell membranes, CCR5 (on T-cells, macrophages and microglia) (Choe et al., 1996; He et
al., 1997; Lederman, Penn-Nicholson, Cho, & Mosier, 2006) and CXCR4 (on T-cells)
(Berger, Murphy, & Farber, 1999). Small changes in the V3 loop of gp120 direct whether a
particular strain will target CCR5 or CXCR4 receptor types.
Following fusion, the virus core enters the cytosol, at which time free viral RT
enables incorporation of the viral genome into host cell DNA (integration). T-cell activation
seems to be required for viral disassembly and the fusion of additional viral particles
(Cleghorn, Reitz, Popovic, & Gallo, 2005; Gowda, Stein, Mohagheghpour, Benike, &
Engleman, 1989). Viral positive-stranded RNA is transcribed into nuclear DNA—even in
resting cells, and it is believed that this is one of the means by which HIV reservoirs may
remain stable for extremely long periods (years or even decades) in resting T-lymphocytes,
monocytes, and macrophages (Cleghorn, et al., 2005).
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Later, when cells undergo division, as in response to clonal expansion following an infection
to which CD4+ lymphocytes respond, virus is produced as well, using host cell regulating
enzymes (transcription) (Streicher, et al., 2000). However, active cell division is not required,
as viral production occurs even when cells are not actively mitotic (Graziosi et al., 1993).
After new viral proteins are generated, viral proteases cleave the new strand of protein, and
other enzymes assemble the virus for budding from the cell surface (Streicher, et al., 2000)
Figure 2.3 depicts the life cycle of HIV and displays multiple drug targets at the fusion,
reverse transcription, integration and protease production stages.

Figure 2.1 Life cycle of HIV.

Figure 2.3. Antiretrovirals target binding, fusion, reverse transcription, proviral
integration, and early assembly. From Cleghorn, Reitz, Popovic, and Gallo (2005).
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Ho et al. (1995) showed that daily HIV production is quite high. Perelson, Neumann,
Markowitz, Leonard, and Ho (1996) found that replication proceeds on the order of 10.3 x
109 virions/day. Richman et al. (2004) demonstrated that an average of one mutation during
each replication of each genome occurs. Mathematical models of HIV replicative error rates
suggest that each day, every possible mutation—including drug resistance mutations—can
occur at least once, and many may occur several times (Coffin, 1995; Perelson, et al., 1996).
It is believed that retroviruses gain survival advantages from this high rate of error, enabling
the frequent appearance of drug-resistance mutations, as well as a rapid rate of replication to
create large numbers of viral particles (Mansky, 1998; Richman, et al., 2004).
Immunological Events in HIV Infection
Early infection. The development of HIV infection begins with inoculation across
broken skin or upon mucosa, usually rectal or vaginal in humans. Here tissue- or mucosaresident dendritic cells (DCs) acquire contact with the virus and transport particles to nearby
lymphoid tissue, chiefly nodal tissue, where T-cell infection is thought to take place in DC/Tcell complexes that are a normal part of the immune response. Evidence suggests that the
DCs are not actively infected, although such cells do express low levels of CD4. It is believed
that the proximity of the T-cells to active virus on the surfaces of DCs leads to the initial
introduction of HIV into host cells for virus production (Dybul, Connors, & Fauci, 2005).
At this stage, serum viral burden may reach 107 virions/mL and may cause acute
retrovirus syndrome, a constellation of symptoms resembling influenza or mononucleosis, as
nonspecific innate mechanisms and cytokines such as interferons are secreted by an activated
immune system (Perelson, et al., 1996; Perlmutter, Glaser, & Oyugi, 1999; Streicher, et al.,
2000). The first antibodies to HIV appear within two weeks in some individuals, but may not
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be detectable by typical commercial antibody assays until six weeks into infection. Early
stage neutralizing antibodies exert no control on the rise of viral burden, with stronger
humoral responses, supported by antibody-bound complement, and activated cytotoxic
lymphocytes (CTL, CD8+lymphocytes) developing in 10-21 days to begin to bring the
infection under control. The rise of this later, complement-binding antibody does seem to
control viral spread (Pantaleo & Fauci, 1996).
Chronic Infection. As serum viral burden decreases in response to the nowinvigorated and specific CTL response, two sources of persisting HIV are believed to be
responsible for latent reservoirs of infection: proviral DNA woven into resting T-helper cells
and follicular dendritic cells (FDCs) in peripheral lymphoid tissue (Pantaleo & Fauci, 1996).
As was noted earlier, retroviruses copy their own genetic code into host target cell DNA
strands. T-helper cells (THCs, CD4+ lymphocytes) are part of a pool of cells that assist
thymic-dependent antibody responses by interacting with MHC-II/antigen complexes on Blymphocytes. Such helper cells also activate macrophages, assist CTL killing of virusinfected cells by inducing proliferation of those cells, and induce cytokine production in
response to infection. A pool of resting THCs may be ―naïve,‖ specific antigen-ready and
unarmed, or they may instead be ―memory‖ cells, with matured antigen specificity and
primed for rapid clonal expansion upon new contact with the ―memorized‖ antigen (Figure
2.4).
In either event, these lymphocytes are critical to initiating adaptive responses to new
pathogens (naïve cells) and initiating rapid responses (with correspondingly lower energy
costs) to previously-presented pathogen antigen (memory cells). The maintenance of the
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Figure 2.2 Idealized Model of T-cell Activity
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memory pool of THCs in particular sustains immune system competence and antigenic
memory over decades (Janeway, et al., 2005).
If it is the quality of the immune response and (Pantaleo et al., 1997) and the number
of T-lymphocytes and other immune cells (Pantaleo & Fauci, 1996; Pantaleo, Graziosi, &
Fauci, 1993) that together determine the level of sustained viremia in HIV patients, it is the
persistence of the pool of resting CD4 cells, assisted by constant low-level stimulation from
FDCs, that forestalls apoptosis, and maintains the infection itself. It has been shown that the
deterioration of the CD4 lymphocyte pool may not even be due to direct killing by virus.
Indeed HIV maintains T-cells as productive virus factories. Rather it may be immune
activation (Sousa, Carneiro, Meier-Schellersheim, Grossman, & Victorino, 2002) and robust
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CTL that depletes the host’s immunity and eventually leads to clinical symptoms (Borrow,
Lewicki, Hahn, Shaw, & Oldstone, 1994; McMichael & Rowland-Jones, 2001). The clinical
events that do result from diminution of the CD4+ lymphocyte pool is discussed further
below.
Late clinical events. Whatever the ultimate cause of the depletion of THCs, over a
period of 18 months to 10 years, most untreated persons will develop some evidence of
clinical disease (Mellors et al., 1997). There is ample evidence to suggest that genetic,
immunologic, and possibly viral causes exist for both rapid, early disease, and nonprogression to clinical AIDS (Berger, et al., 1999; Cao, Qin, Zhang, Safrit, & Ho, 1995;
Graziosi, et al., 1993; Haynes, Pantaleo, & Fauci, 1996; Pantaleo, et al., 1993; Wei et al.,
1995). Although it has been suggested that clinical progression in HIV disease may be a
result of immune activation or immune dysregulation, opportunistic infection remains a
significant cause of morbidity and mortality. Major primary causes of death worldwide from
HIV include tuberculosis and Streptococcal pneumonia. Other causes are cervical neoplasia,
lymphoma, and other cancers, especially those associated with certain viral infections, such
as Kaposi’s sarcoma (associated with herpes simplex 8 infection) (Roizman, 1995). Thus,
whatever factors cause sickness in HIV-infected patients pharmacologic suppression of virus
remains the mainstay of treatment. This fact provides the impetus for this proposed study: If
drug therapy matters, and if adherence matters, then means to maintain that adherence matter
to nurses who treat HIV/AIDS patients.
Antiretroviral Therapy and its Implications: The Bases for ART Today
Zidovudine (ZDV) is a thymidine analogue that was found to be efficacious in the
inhibition of the integration phase, though its blocking of reverse transcriptase at the coding
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target (Furman et al., 1986; Parks et al., 1988; Shiau, Schinazi, Chen, & Prusoff, 1980;
Uherova, Schmidtmayerova, & Mayer, 1991). Ultimately, single-agent therapy did not reduce
significantly longer term mortality in AIDS patients, and there was evidence that the virus
was becoming resistant to ZDV and that toxicity limited treatment tolerance (Rachlis, 1990).
Zidovudine did not significantly alter the course of the disease (Volberding et al., 1994), and
single class regimens of several nucleoside analogues were not any more successful
(HIV_Trialists_Collaborative_Group, 1999), and could be antagonistic (Havlir et al., 2000).
In the mid-1990s multi-drug therapy studies in parallel with the development of
polymerase chain reaction (PCR) techniques that allowed direct measurement of virus in
serum, led to the conclusion that multiclass ART could hold the key to more durable
effective treatment (Collier, Coombs, Schoenfeld, Bassett, Baruch, et al., 1996; Collier,
Coombs, Schoenfeld, Bassett, Timpone, et al., 1996; Danner et al., 1995; Eron et al., 1995).
A multi-center cohort study by Mellors, et al. (1997), showed that prognosis varied
proportionally to viral load and inversely with CD4 counts. This seemed to suggest that
durable, constant suppression of virus could forestall immune decline from HIV infection.
These studies seemed to suggest that saving HIV patients could be accomplished through
attacking the life cycle at two or more points (Gulick et al., 1998; Gulick et al., 1997;
Hammer et al., 1996; Hammer et al., 1997; Palella et al., 1997). Recent data demonstrate that
potency alone may not be enough to control HIV, as ―triple nucleoside‖ regimens proved
inadequate to provide long term control for patients with serum viral loads above 100,000
copies/mL (Gulick et al., 2004). Inhibitors of the RT enzyme itself (as opposed to inhibition
of its substrates, e.g., thymidine), inhibitors of protease, and more recently, inhibitors of
fusion have been combined with nucleoside RT inhibitors, such as ZDV, to create effective
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multiclass ART (Palella, et al., 1997; Panel_on_Antiretroviral_Guidelines_for_Adult_and_
Adolescents, 2006; Sepkowitz, 2001).
Antiretroviral Resistance and Adherence
The dynamics of HIV, the consequence of unchecked infection, and the effectiveness
of multiclass ART were explained in previous sections. To summarize: HIV ―writes itself‖
into the genetic code of host cells, chiefly CD4+ lymphocytes and macrophages. Viral
elimination may not be possible: resting memory T-cells may harbor proviral DNA for
decades, sequestered from the action of available drug therapy (Finzi et al., 1999).
Replication proceeds with many errors, yielding inactive virus, but also yielding some
adaptive mutations. Thus, the cornerstone of ART now is the creation of regimens that
effectively shut down viral replication. If there is no replication, there can be little to no
opportunity for the creation of drug resistance mutations (Patel & Patel, 2006).
Viral replication commences relatively soon after serum drug levels fall below their
inhibitory concentrations (Blaise, Clevenbergh, Vaira, Moutschen, & Dellamonica, 2002;
Tobin et al., 2005). The goal of ART is to maintain constant, therapeutic drug levels. Missing
doses may lead to drug levels falling below those levels. There are many reasons for nonadherence, including patient preference or competing life goals, various behavioral or
psychological impediments such as substances abuse or low self-esteem, and socio-economic
problems to include changing residence jurisdiction (e.g., for patients on public assistance),
and so forth (Benedetto, 2003; Chesney, 2000; Marhefka, 2002; Ramirez & Cote, 2003). The
present study was concerned with non-adherence related to unpleasant side effect symptoms,
whether they are from the actions of the drugs or from psychosomatic effects, such as nocebo
or context effects.
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Variations in adherence have been characterized based on dosing frequency alone
(Mannheimer, Friedland, Matts, Child, & Chesney, 2002) and dosing frequency versus dose
timing (Ferguson et al., 2005), with the former having been better studied. An ideal
adherence level of >90% of doses taken is associated with durable viral suppression (Robert
Gross et al., 2006; Lowe, Prins, & Lange, 2004; Press, Tyndall, Wood, Hogg, & Montaner,
2002). The high rate of replicative error combined with loss of viral suppression leads to the
emergence of viral resistance (De Olalla et al., 2002; Rouzine & Coffin, 2005).
Thus, the goal of ART is to suppress virus and spare the immune system both CD4 T
cell depletion and excessive chronic activation. Clinical deterioration has been shown to
correlate well with levels of CD4+ lymphocytes (Fahey, et al., 1990). Suppression of virus
leads to a restoration of certain immune cell subsets, and has been shown to thus lead to
immune reconstitution and clinical improvement (Hung & Chang, 2004). If patients cannot
adhere because of side effects, or suffer too long from feeling ill on ART, adherence can
suffer, and this can lead to loss of suppression outright (when medications are halted) and/or
drug resistance (when medications are taken correctly less than 90% of the time) (Press, et
al., 2002; Rouzine & Coffin, 2005).
Summary
Infection with HIV is persistent, and at present permanent, due to the unique way that
retroviruses become part of the host cell genome. Infection is highly dynamic and results in
significant immune system activation. Infection also targets specific human immune cell
types that lead to weakening of immunity, and opportunistic infection is a late and often fatal
result. Persistence of the virus owes to persistence of very specific THC subsets that are long-
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lived. Although virus may be suppressed for years, small numbers of resting THCs are
enough to seed a full-scale reinfection if drug pressure is removed.
The dynamics of HIV result in many mutations, and drug resistance mutations are a
daily occurrence, but competition with wild-type virus limits its persistence in the host. Drug
pressure suppresses viral replication and also limits the emergence of drug resistance.
Intermittent use of ART or the use of incomplete regimens lead to incomplete suppression,
and drug resistant variants emerge. These variants lead to viremia despite therapy, and the
clinical consequences of unchecked HIV infection can resume. The effectiveness of entire
classes of antiretroviral drugs can be lost.
For these reasons, ART is currently considered a lifelong therapeutic enterprise.
Interruptions are not usually catastrophic, but can only be short-lived in most patients.
Reasons for interruption include drug toxicity. Otherwise, patients must remain on ART
continuously. Minimizing side effect symptoms assists the goal of adherence, and continuous
adherence is, for now, the only effective long term treatment strategy in HIV disease.
Educating Patients for Adherence to Antiretroviral Therapy
From early in the era of ART it was observed that failure to adhere to medications
properly can lead to drug resistance (Bangsberg, 2006; Bangsberg et al., 2000; Blaise, et al.,
2002; Tobin, et al., 2005), that this can lead to poor clinical outcomes (De Olalla, et al.,
2002; Press, et al., 2002; Richman, 1994), and thus requires diligent efforts toward improving
patient adherence to the regimens as prescribed (Esch & Frank, 2001). ―Adherence
education‖ or ―adherence training‖ are terms that have arisen in the clinical vernacular of
HIV specialist clinicians whose patients often expect to actively participate in their care
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choices, an outcome of the activist politics surrounding the HIV epidemic. This raises the
question: In HIV treatment, what is adherence education?
Teaching patients how to utilize a prescribed regimen is probably one of the oldest
interventions in human history, and Hippocrates referred to patients who did not take their
medications for various reasons (Vermeire, et al., 2001). It is beyond the scope of this project
to review everything known about teaching patients how to use their medications. However,
establishing that regimens are complex, that failure to take the regimens properly can have
serious consequences, and that therefore adherence has special significance in ART calls for
a discussion of adherence as it applies to ART. It is also important to note that reviews of
―patient compliance‖ tend to devolve to a few issues. Patients choose to adhere to medical
regimens when the expected gain exceeds the perceived losses—in time and inconvenience,
in suffering due to side effects, in their sense of social stigma (especially pertinent in disease
like HIV/AIDS) (C. Golin, Isasi, Bontempi, & Eng, 2002; Wilson, Hutchinson, & Holzemer,
2002). Also important is that patients believe that their concerns about treatment have been
heard and have formed part of the plan (Dunbar, 1980; Lieberman, 1996). Yet as Chesney
(2003) notes, substance abuse, domestic violence, transience of habitation, loss of insurance
and other issues have significance as well. These issues could be subsumed under the rubric
―readiness to therapy.‖ But readiness to therapy is more complex than that. There is also the
notion of a diffuse, highly personal sense of ―readiness‖ for any medical undertaking
(Bartlett, 2002) that has become well-recognized in HIV/AIDS care. Putting this individual
and personal sense of readiness together with actual social impediments to therapy, gives a
more complete definition to ―patient readiness.‖
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Lucas, Chaisson, and Moore (1999) report that availability of social support systems,
patients’ ability to fit medication dosing into their routines, and the sense that they can dose
without stigma (take HIV medications in front of others) contribute to adherence.
Furthermore, when patients keep clinic appointments, and when they understand that missing
doses or taking doses late leads to viral resistance, adherence predictably improves. The
Panel on Antiretroviral Guidelines for Adults and Adolescents (PAGAA) (2006) advises that
a ―trusting relationship‖ among patient and health care team is essential (p. 2), and that
continual communication between patient and team contribute to readiness to therapy as well
as adherence. Active substance abuse (Sherer, 1998), untreated mental illness (Kemppainen
et al., 2004; Uldall, Palmer, Whetten, & Mellins, 2004), and current living status may
interfere with readiness and need to be considered as part of adherence readiness assessment
and education planning (PAGAA, 2006). Next, a suggested standard of care for adherence
training is considered.
In a study by Murphy, Lu, Martin, Hoffman, and Marelich (2002) several features of
what many clinicians would consider to be a ―good‖ adherence training approach were
employed in a pilot among 33 patients on ART. Those features include individualized
training sessions to discuss readiness for ART, incorporation of the regimen into the patients’
lifestyles, and also strategies not commonly employed in clinics such as group sessions to
explain treatment rationales, how adherence influences the development of drug resistance,
and so forth. In this study, ―standard care‖ was less formal and was described as ―the regular
care provided by the clinic as its normal policy‖ (Murphy et al. p. 60). The authors go on to
state that this consisted of
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…the usual inquiries at regular appointments as to difficulty with adherence; those
reporting problems received a single 30-minute consultation, had their medication
schedule written down for them, and received no further intervention. (Murphy et al.,
2002, p. 60)
A study by Safren, et al. (2001) highlights the difficulty in coming to a common
definition of ―standard of care‖ in preparing a patient to take a complicated regimen of fairly
toxic medication, and in which non-adherence may have significant health consequences over
the long term. In their study of the use of two psychobehavioral strategies to enhance
adherence, the control group or patients in the ―self-monitoring condition‖ (p. 1155) the
authors do not even describe what initial education patients received about dosing, what to do
on ―sick days,‖ and other potential conditions noted above in the material from University of
California San Francisco and AIDS Education and Training Center. In the ―Life Steps
[intervention] condition‖ the group received interventions that included ―eleven
informational, problem-solving, and cognitive-behavioral steps for improving adherence…‖
which include ―obtaining medications…formulation of a daily medication schedule…‖ and
―cues for pill-taking‖ (p. 1156). Also included are strategies such as guided imagery (GI).
The problem is that many of their intervention strategies are included in current educational
interventions undertaken by clinicians, nurses, and pharmacists, depending on who is
assigned to the task in any given clinic. In the researcher’s experience it is common for
several such points to be covered in varying depths by several such agents in a given patient
visit—especially if a new regimen is being prescribed, or there has been a change in one or
more agents in the regimen. Since the beginning of combination ART for HIV, clinicians and
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others involved in care have been teaching patients about dosing times and other items in the
list of the intervention by Safren et al.
That clinicians and other staffers may not always address the items noted in the lists
above in the same way, style, depth, or detail was the subject of a study by Golin, Smith, and
Reif (2004). They sought information about the adherence training habits of a sample of 589
physicians in North Carolina. With a response rate of 63%, 369 respondents reported
spending an average of 13 minutes counseling patients who were starting a new or changed
regimen, and covered an average of seven of 16 ―counseling behaviors‖ on a checklist
developed by the researchers, adapted from items from the Adherence and Efficacy of
Protease Inhibitor Therapy Study (ADEPT) provider adherence behavior scale, The United
States Pharmacopeia (USP) Medication Counseling Behavior Guidelines, and U.S.
government guidelines for Medicare. The authors concluded that physicians treating
HIV/AIDS patients need additional training in adherence as well as more time to deliver the
messages that support adherence. This researcher’s question would be: Given the immense
amount of information available in every form: oral presentations, journal articles, websites,
and even colleagues in nursing and pharmacy, is it really a problem of ―lack of training‖?
Conclusion
Adherence education is an important part of how patients acquire facility with their
medical regimens. Several authorities propose very similar schemes to assure that patients
understand the goals of drug therapy, special features of the regimen (e.g., timing with
meals), and how to manage side effects, as well as the consequences of nonadherence.
Evidence suggests that adherence education in the clinic is variable. On the one hand, it is
necessary to assess patients’ knowledge and capabilities and to adapt education appropriately.
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On the other hand variability and missed opportunities are common. Reconciling these two
issues for this study is discussed in the chapter on methodology.
Cognitive-Behavioral Therapy for Symptom Management
Much of the research into the management of symptoms using CBT involves
cancer—either the symptoms of the disease itself, or symptoms that arise from treatment.
Such experience forms a basis for the proposed study.
It was during the time of burgeoning research into the so-called ―mind-body
connection‖ during the 1970s, that pharmacological and radiological interventions for cancer
were also gaining greater success against the disease. Such therapies came with serious side
effects, ranging from local and systemic pain, to nausea/vomiting, debilitating fatigue, and
even anxiety related to such adverse effects, a condition of their use that still obtains today
(Golden, 1975; Sausville & Longo, 2001; Schnell, 2003). This resulted in a number of
investigators looking into whether techniques effective in achieving autonomic control could
also be effective in helping cancer patients achieve greater comfort during treatment cycles.
Indirectly, this might improve adherence or willingness to continue chemotherapy. The next
section reviews the literature on the management of symptoms, with emphasis on symptoms
in cancer and HIV.
Nausea and Vomiting. One of the thornier problems in antineoplastic therapy is that
of control of nausea and vomiting (Grunberg, Hansen, Deuson, & Mavros, 2002). Most
patients find these symptoms highly aversive, and their control is considered one of the keys
to successfully engaging patients in continuing chemotherapy. Promethazine,
metoclopramide, corticosteroids, and a host of other antiemetics have been used to relieve
nausea (Morrow, Roscoe, Hickok, Andrews, & Matteson, 2002; Schnell, 2003). At the time
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of this writing, the 5-hydroxytryptamine-3 receptor (5-HT3) antagonists are demonstrated to
be the most effective pharmacologic means of controlling nausea and vomiting (NCCN,
2005). It is understood that serotonin, released from enterochomaffin cells in the small
intestine, activates the chemoreceptor trigger zone (CTZ) during some antineoplastic therapy
(Schnell, 2003), but what is not understood is why agents such as cisplatin,
cyclophosphamide, and doxorubicin have such a high emetogenic potential in this regard.
Nevertheless, such agents can be reliably expected to produce nausea and vomiting in most
patients (60-90%) (Schnell).
Two conditions related to nausea in antineoplastic therapy cause patients to continue
to suffer from the symptom. The first is that although antiemetic therapy has become more
effective (Gralla et al., 1999; Grunberg, et al., 2002), not all patients respond to it with
complete or significant reduction in discomfort (Gralla, et al., 1999). Second, if control is
lacking, and depending on the sensitivity of any given patient to distress related to nausea,
some patients become conditioned to expect the nausea and vomiting, and this may lead to
ANV (Burish & Carey, 1986; Zachariae et al., 2007). Cancer patients may grow ill on the
way to the clinic, or the day prior to a treatment round, or even in situations that remind them
of chemotherapy (such as a dentist’s office) (Morrow et al., 1992; Morrow, Roscoe, Kirshner,
Hynes, & Rosenbluth, 1998; Schnell, 2003). Zachariae et al.(2007), using several scales of
sensitivity and reactivity (Tellegen Absorption Scale, the Somato-Sensory Amplification
Scale, and the Autonomic Perception Questionnaire) found that ―openness‖ to absorbing new
situations, and suggestibility tended to increase ANV. A review by Morrow, Roscoe, Hickok,
and Matteson (2002) supports the view that while newer antiemetics are more effective,
nausea and vomiting—anticipatory and otherwise—remain a clinical problem in
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antineoplastic therapy. Both medical and behavioral techniques are required to fully address
the biological and behavioral reasons for the symptoms.
Behavioral Interventions in Nausea and Vomiting in Antineoplastic Therapy
Several studies have shown that relaxation training that helps patients moderate their
anxiety may significantly reduce conditioned responses that lead to ANV. Dempster, Balson,
and Whalen (1976) describe a case utilizing hypnotherapy as a means to reduce anticipatory
nausea and anxiety in a female undergoing antineoplastic therapy with nitrogen mustard for
Hodgkin’s disease. She responded well to the intervention and was able to continue with her
therapy. She also expressed more ―hopeful feelings‖ (p. 7) about being able to live with her
disease and the treatment.
Burish and Lyles (Burish & Lyles, 1979) found that relaxation training allowed a
woman to successfully tolerate chemotherapy for lymphoma. Consequently, they followed
this with a small trial of 14 participants (cancer type not stated) (Burish & Lyles, 1981) and
demonstrated significant (p<.05) improvements in mood (anxiety, anger, and depression as
measured by the Multiple Affect Adjective Checklist) and post-treatment nausea (verbal
Likert scale developed by the authors) as well as lower physical arousal (pulse rate;
differences in blood pressure were non-significant). Similar studies with similar designs and
dependent measures confirmed significant trends toward lessened nausea, improvements in
mood, and decreased arousal (Burish, Carey, Krozely, & Greco, 1987; Burish & Jenkins,
1992; Burish, Snyder, & Jenkins, 1991; Burish & Tope, 1992; Carey & Burish, 1988).
Morrow et al. (1992) were able to show that techniques such as progressive muscle
relaxation, directed at reducing nausea in cancer patients undergoing antineoplastic therapy,
were generally safe and effective even when delivered by nurses or oncologists. A
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psychologist or therapist did not have to be present to deliver such interventions. The authors
note that medical personnel should not engage patients in psychotherapy or other
interventions that might require the spectrum of skills that would require special training in
psychology.
One negative study by Syrjala, Cummings, and Donaldson (1992) found that hypnosis
did not significantly reduce symptoms of nausea (although it did reduce oral pain) in the
treatment arm of a trial of 67 bone marrow transplant patients. Distraction as a technique, was
tested against relaxation in 60 patients assigned to one of six groups in a 2 x 3 factorial
design, based on their pre-intervention level of anxiety, and to either intervention or the
control condition (Vasterling, Jenkins, Tope, & Burish, 1993). There was no difference
between the interventions; both significantly reduced nausea and physiologic arousal (blood
pressure).
Over the last several decades, it has been shown that behavioral management is an
important adjunct to medical therapies directed at relieving nausea in antineoplastic therapy
(Redd, 1994). Later reviews that attempted to determine the most effective behavioral
approaches have shown that techniques that reduce physiological arousal and induce trance
or semi-trance states such as hypnosis, and relaxation, and cognitive techniques such as
guided imagery exert the greatest effects in symptom reduction (Mundy, DuHamel, &
Montgomery, 2003; Redd, Montgomery, & DuHamel, 2001).
Behavioral Interventions Used to reduce Pain: Acute pain may be managed
through cognitive/behavioral means (Chen, Joseph, & Zeltzer, 2000; Kuttner, 1989; Logan,
Baron, & Kohout, 1995; Rusy & Weisman, 2000; Tan & Poser, 1982). Chronic pain presents
more challenge, and chronic pain has drawn significantly more attention in terms of CBT
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interventions (Adams, Poole, & Richardson, 2006; Eccleston, 2001; Frischenschlager &
Pucher, 2002; Morley, Eccleston, & Williams, 1999; Nielson & Weir, 2001; Turk, 2003)
Perhaps this owes to the fact that analgesics are often effective for short-term pain, and acute
pain often has a definable proximate cause (e.g., appendicitis, sprain, side effects from
drugs).
By the mid-1980s a small number of studies had tested the effectiveness of CBT in
the management of cancer pain. Caudell’s (1996) review mixed studies of pain, ANV, and
anxiety, as well as great variety of CBT interventions (e.g., distractions, relaxation, etc.)—as
well as non-CBT interventions such as Therapeutic Touch—and concluded that such
therapies could easily be included in nursing practice, but spoke with less certainly to
whether such therapies are effective. It can be argued that Caudell’s review, while admirable
for its humanism, did not apply adequate inclusion criteria to her review.
Morley, et al. (1999) contributed a meta-analysis of chronic pain management in
patients other than those with cancer. Twenty-five papers met inclusion criteria, and
diagnoses included musculoskeletal and neuropathic pain of various types but excluded
headache. They concluded that significant effect sizes occurred for all intervention groups,
when controls were applied for variations in measurement reliability. In another metaanalysis (McCracken & Turk, 2002) of pain other than that caused by cancer, patients’ sense
of control and willingness to participate in their pain management was significantly
correlated with effect sizes.
A panel at the U.S. National Institutes of Health (Anonymous, 1996) determined that
psycho-behavioral interventions are a useful adjunct in chronic pain management. The
strongest evidence for efficacy was for hypnosis and relaxation techniques alone, and
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moderate effects for cognitive behavioral therapy (which may or may not include those
specific behavioral techniques, as ―cognitive behavioral therapy‖ encompasses a large subset
of behavioral supports).
Devine and Westlake (2003) reported on a meta-analysis of 25 studies of adults with
cancer pain and the use of CBT. Methodological quality varied considerably; several trials
did not employ random assignment. When the analysis was limited to better quality studies, a
statistically significant improvement in pain control remained evident, with the most
effectiveness seen in trials employing relaxation techniques. In a review (Semple, Sullivan,
Dunwoody, & Kernohan, 2004) of the use of psychological interventions as adjunctive pain
management in head and neck cancer, studies tended to support the effectiveness of CBT
over other psychological interventions. Tatrow and Montgomery (2006), in a meta-analysis
of 20 studies of CBT to reduce distress and pain in breast cancer patients found that CBT
effect sizes were .49 reduction of pain regardless of whether or not metastasis had occurred.
Effect sizes for reducing distress were more modest, averaging .31.
As in the case of nausea and antineoplastic therapy, the perceptions of pain were
reduced with CBT, with particular effectiveness of interventions that employed relaxation or
hypnotic-type therapies (and guided imagery may be said to obtain this categorization, since
it is typically employed after induction of relaxation by other means). Note that this review
does not distinguish between pain caused by antineoplastic therapy and pain caused by cancer
itself. The meta-analyses above focused on studies of pain as experienced by the cancer
patient regardless of cause, the exceptions being the reviews by Redd et al. (2001) and
Mundy et al. (2003).
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Note on the Pain and the Side Effects of ART. It is a generally-accepted axiom of
nursing that pain is whatever the patient says it is, and an assumption follows that pain may
not have a definable, relievable pathophysiological cause. It is also axiomatic such an
assumption arises from exclusion of treatable causes. In clinical experience HIV/AIDS
patients have complained of ―pain‖ related to ART, but not always pain that could be related
to known side effects or toxicities that are ordinarily accompanied by pain. Conversely,
pain—or any symptom—may arise from a problem with a given medication. For example,
zidovudine may cause lactic acidosis with accompanying abdominal pain (GlaxoSmithKline,
2005). Johnson, Stallworth, and Neilands (2003) examined the causal attributions of
symptoms held by HIV/AIDS patients: disease, medicine, or neither (i.e., a non-HIV, nonART cause, such as reflux disease, heart disease, etc.) They found that such patients
generally assigned certain types of symptoms, e.g., adenitis, to the disease. This agrees with
what most patients are told about the symptoms of HIV disease. Side effect symptoms tended
to be those that could be temporally related to the start of ART or related to dosing times.
Their study found that in either case, side effect or disease symptom, correct attribution is not
always certain. Patients may mislabel symptoms as side effects and vice-versa, creating
problems for clinical interpretation, especially if information is omitted by the patient
because they believe a symptom unrelated to medication. More to the point with respect to
the current review, is that there is no solid line between symptoms attributable to disease
states or ART side effects.
In general, CBT is effective for chronic pain, and evidence supports the use of CBT in
cancer/cancer treatment pain. In particular, effectiveness was seen with the inclusion of
hypnotic and relaxation-based interventions in this population.
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Behavioral Interventions in Fatigue. A search for studies that utilized a cognitive,
behavioral or dual therapeutic intervention (CBT) to reduce fatigue in cancer patients,
returned three studies. Levesque, Savard, Simard, Gauthier, and Ivers (2004) employed
cognitive therapy as an intervention for depression in cancer patients in a single group
pretest/posttest design. Depression improved, as well as associated symptoms such as
anhedonia and fatigue. Given et al. (2004) conducted a randomized clinical trial using CBT
as the experimental intervention. Fifteen symptoms were measured by severity on 11-point
rating scales (0-10); the scores were then summed to create a scale from 0-150 global score.
The intervention included cognitive approaches (e.g., skills development, self-persuasion,
problem solving) and behavioral methods, although these are not specifically reported, as
they were tailored to each patient’s needs. Global symptom scores improved at 10 and 20
weeks, but the report did not break down the analysis by individual symptom. A very similar
study a year later (Sherwood et al., 2005) also demonstrated improvements in symptom
scores at 10 and 20 weeks, and again the symptoms were not individually analyzed. A single
randomized trial that addressed CBT and fatigue in female HIV patients (Lechner et al.,
2003) utilized a cognitive-behavioral stress management/expressive-supportive therapy
intervention to improve quality of life (QOL), operationalized with the Medical Outcomes
Study 30-item (MOS-30) scale for HIV. The intervention group demonstrated a statistically
significant improvement in total MOS-30 scores by analysis of variance (p<.05) and overall
health distress and health perceptions (p<.001), but fatigue, and single-item scores did not
change significantly.
Fatigue is a common symptom in HIV patients, and it stems from several causes,
some treatable with medication, hygiene, or regimen changes. Other causes are less certain.
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Few studies exist—in oncology or HIV care—that examine the effectiveness of CBT in
treating this symptom.
Anxiety. Anxiety presents a special case. Not only is anxiety itself uncomfortable for
the patient, but it tends to potentiate other symptoms. Sternbach (1975) noted that anxiety
aggravates pain and suggested the exploration of biofeedback as one means of reducing the
anxiety that is both associated with pain, and worsened by it. In the discussion of Burish and
Lyles’ (1979) 30-year-old cancer patient with side effect symptoms, her negative affect
decreased with CBT and this was associated with concordant decreases in other symptoms
such as pain and nausea. In a trial by Lerman, et al. (1990) coping styles that featured
information gathering and ―monitoring‖ were associated with heightened anxiety. The higher
levels of anxiety correlated with increases in nausea and other physical side effect symptoms
in those participants. Coping styles that employed distraction were associated with less
anxiety and also blunted physical side effects. Kalichman (1995, pp. 223-224), argues that
shifting HIV patients’ locus of control inward helps them to assert power in their own
cognitive domain. Since the cortex—thought—is the final common pathway of symptom
experience, it seems logical that any therapy that reinforces the patients’ power over thoughts
could be expected to blunt or otherwise alter such symptoms as they are experienced.
Starcevic (2006) reviewed conceptual and treatment issues in anxiety and reports that
CBT is effective at treating the disorder, not only in clinical trials but in routine clinical
settings. In their review of CBT used to treat ―ordinary‖ psychiatric problems such as
depression and anxiety, Hollon, Stewart, and Strunk (2006) found that medications were
largely palliative, while CBT interventions seemed to show a trend toward more enduring
effects. The effects could not be accounted for by methodological issues alone. However,
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they do not conclude whether this trend to improvement is the result of ameliorations of
factors that led to illness, or to the mobilization of patients’ own psychological skills.
Two meta-analyses were conducted by Sheard and Maguire (1999), one for
depression (20 trials) and one for anxiety (19 trials), in cancer patients treated with
psychological interventions. Most of the studies used CBT or some variant of CBT.
Psychological interventions had a negligible clinical effect on depression, and a moderate
effect on anxiety (mean effect size .36), with the most robust effects seen in four trials that
focused on prevention (.94) of anxiety. In summary, CBT is effective in reducing anxiety,
although it is not certain how much improvement represents individuals’ adaptations over
time, and the role of medications and other medical changes.
Antiretroviral Therapy and CBT
Side Effect Symptoms and Adherence to ART. Several studies looked at the impact
of side effects on patients taking ART. Ammassari et al. (2001) undertook a multicenter,
descriptive study that examined correlates of adherence. Patient’s level of side effects on a
16-item symptom questionnaire significantly inversely correlated with level of adherence,
with greater number and intensity of side effects associated with lower levels of adherence.
Brook et al. (2001) examined reasons patients chose to skip doses and/or discontinue
otherwise successful regimens in a twelve-center study in England. Lack of motivation was
found to have the largest impact leading to poor adherence, but side effects were a
statistically significant factor in their descriptive study.
Regimen selection has been proposed as a means of improving adherence, based in
part on a study by Miller, Huffman, Weidmer, and Hays (2002), which found that anticipated
side effects have an impact on patient preferences for various regimens. The authors argue
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that factoring anticipated side effects and patients’ individual tolerance for various such
effects could improve adherence, and improve clinical endpoints. A grounded theory study
by Wilson, Hutchinson, and Holzemer (2002) proposed a theory of nonadherence that
encompassed self-identity, illness ideology, concurrent treatment regimens, the meaning of
time, medication burden and side effects, and lifestyle, that coalesce to produce a state of
mind that shapes adherence choices on a dose-by-dose basis. Some of their suggestions for
intervention include education about side effect management, with reframing among them.
No studies have specifically tested this theory. Based on the foregoing work, subsequent
studies have explored the educational and the cognitive/behavioral approach, respectively. In
a prospective pilot study, medication adherence improved with the use of weekly medication
counseling sessions, focused on various management issues, and including a pill organizer
(McPherson-Baker et al., 2000). Similar results were found in a prospective study of 997
patients (Weiss et al., 2003). Knowledge about ART was significantly associated with
adherence. Using logistic regression analysis to analyze the number of correct questions out
of five, fewer than four correct answers increased the odds of self-reported nonadherence
(OR = 1.72 for 2-3 correct, p<.01; OR = 2.92 for 0-1 correct, p<.05). Gellaitry et al. (2005)
studied patient satisfaction with medication education in 115 participants. Using a validated
questionnaire, the authors found that patients who reported less satisfaction with the
information they received about ART to be more likely to decline therapy (p<.05). Declining
ART was significantly associated with concern about potential adverse effects of therapy
(p<.001).The authors conclude that individualizing education may improve acceptance of
ART. The most significant feature of these studies is that the dependent variables were all
based on patient adherence, with clinical endpoints (CD4 and HIV RNA) not measured—
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these were assumed to improve because of adherence, as noted in earlier sections of this
paper.
A review by Haddad et al. (2005) of the available trials of educational interventions to
improve adherence, found that only one trial included the a comparison group and a measure
of adherence. Their conclusion was that only a pharmacist-led educational intervention
improved adherence significantly. Improved adherence in that study was associated with viral
loads below the limit of detection, regardless of participation in the intervention. In other
words, participating in the intervention did not statistically predict undetectable viral load,
only improved adherence, regardless of how patients got there. The authors also noted that
more trials looking at clinical endpoints should be considered for study.
The Use of CBT in ART. The review sought to answer two questions. The first
question asked to what extent have CBT approaches been used to either mitigate symptom
side effects in ART, or to improve adherence (whether or not symptom control was tested)?
The second question asked if such techniques have been used, which techniques were most
effective in HIV/AIDS and ART?
During the period February 2004 to December 2006 a series of searches were
conducted in Pubmed/MEDLINE, CINAHL, and PsyLIT databases. Search terms that would
encompass cognitive-behavioral therapy (e.g., ―cognitive therapy,‖ ―behavioral therapy,‖
―relaxation‖) were joined with terms to encompass ART/therapeutics, medication
adherence/compliance, and HIV and/or AIDS. In the most recent search, 18 studies were
cataloged. Six of these studies met the criteria for inclusion: An individualized cognitive,
behavioral, or combination approach was the intervention in a clinical trial, pilot study with
or without control, or case series. The intervention could affect any variable related to
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adherence or symptom control (including mood, or cognitive processes that could help
improve mood). The six studies are summarized below.
Using a pre-test/post-test design among Taiwanese HIV patients, Chiou et al. (2004)
found that fewer hospital visits occurred among HIV patients on ART when an educational
intervention was used to teach management of side effects. This three-arm trial compared a
control group, and two experimental groups, one which received a group therapy
intervention, and the other which received individualized therapy. The control received
―standard‖ teaching on medication use. Hospital visits decreased in both group and
individualized interventions, but there was no statistical difference between the two groups.
Although the clinical endpoints for HIV and adherence were not studied, the authors
conclude that a reduction in hospital visits reduces burden on the health care system and
gives HIV patients on ART the tools to manage side effects effectively. The study was
included here based on the assumption that symptom control could serve as a reason a patient
would visit the hospital (―visit‖ included visits to emergency wards, even if the patient was
discharged the same day).
The remaining four studies examined the impact of CBT. Two small studies (Ironson
et al., 2001; Murphy, et al., 2002) examined the use of CBT to increase self-efficacy among
HIV patients, as it affects adherence, clinical endpoints, and perceived distress. Murphy, et al.
(2002) sought to test the hypothesis that enhanced self-efficacy—the ability to assert oneself
with clinicians, ask questions, report problems, etc.—would lead to improvements in
adherence, less distress, and greater life satisfaction. Twelve participants were randomized to
receive standard medication education (SME) or SME and cognitive/behavioral interventions
designed to enhance self-efficacy (e.g., coping strategies, engaging social support).
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Reframing, relaxation, and distraction, were not among the CBT techniques used, and there
were no CBT interventions devoted solely to management of side effects or distress related to
side effects. A statistically significant improvement in self-efficacy was found using the
Antiretroviral Medication Adherence Coping Strategies Scale, which was used to measure
patient-physician communication, social support, and acceptance of need for medication
(p<.05). However, there was no significant difference between groups for adherence,
measured by self-report (although the authors report a trend toward significance). This may
result from the small number of participants (n = 33).
Ironson et al. (2005) looked at whether CBT might have an impact on self-efficacy
and disease markers (CD4 and viral load). In a randomized, controlled clinical trial with 56
women, the researchers tested the question: does self-efficacy improve clinical endpoints in
HIV disease? Fifty-six women were randomized into intervention and control groups. The
intervention targeted general measures of self-efficacy, operationalized in a self-efficacy
measurement tool developed by the authors. The actual intervention emphasized reframing
thoughts about ART, developing assertive responses (e.g., asking questions when some
technical aspect of ART wasn’t understood clearly), and relaxation techniques. Clinical
endpoints improved in the intervention group; the results were statistically significant.
Adherence was not measured. However, the authors discuss that it is unclear as to how or
why CD4 counts improved and viral load decreased: was it greater adherence or some as-yetunder described effect of thought on the subjects’ immune systems?
Two studies (Jones et al., 2003; Parsons, Rosof, Punzalan, & Di Maria, 2005)
examined the how the choice of CBT strategy might change adherence. Jones et al., in a
study of 174 low-adhering women randomly assigned 82 women to a ten-session psycho-

40

educational intervention, based on principles of cognitive therapy and stress management,
that was designed to encourage the women to express their concerns, beliefs, and knowledge
of ART, including its potential impact on their lives and the courses of their disease. The
intervention was intended to improve coping, and was not designed to improve adherence,
although it was hypothesized that adherence might improve. Denial-based coping did
improve in the intervention group, and low-adhering women did increase their self-reported
adherence by 30% (p<.01) Adherence in the control group did not improve.
The study by Parsons et. al. (2005) focused on substance abuse as a main factor
contributing to non-adherence. They sought to test a cognitive-behavioral intervention that
would prevent relapse as well as preventing behaviors in which substance abuse would
interfere with regular ART dosing. As in the study by Jones, et al. (2003) the intervention
was based heavily on engaging cognitive processes, through the use of classical cognitive
therapy and motivational interviewing. Eleven participants completed the full eight weeks of
sessions with the therapists, and the remaining four completed between two and six sessions,
with twelve participants available for the final three-month follow up evaluation. The authors
report that the study was too small to show an effect. However, a non-significant trend
toward improved adherence was evident.
Two studies (Molassiotis et al., 2002; Molassiotis, Lopez-Nahas, Chung, & Lam,
2003) sought to examine the impact of CBT on adherence. In a pilot study (Molassiotis, et
al., 2002) of 46 Chinese patients that used a group CBT intervention there was a statistically
significant improvement in both mood (Profile of Mood States) and quality of life (World
Health Organization Quality of Life-BREF-HK Scale). Because it was a group intervention,
it does not strictly meet the criteria for this review. It is included here because it formed the
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basis for a second study by Molassiotis, Lopez-Nahas, Chung, & Lam (2003), 12 Chinese
patients using individualized CBT, with most of the emphasis on cognitive strategies,
especially education about medication use. This study also found statistically significant
improvements in adherence (self report) and CD4 counts in the intervention group (t-test of
means from AIDS Clinical Trial Group [ACTG] Adherence questionnaire, p<.05). The
authors conclude this is due to greater adherence to medications. The five studies that focused
on individualized interventions are summarized in Table 2.1.
Discussion: The use of CBT in improving symptom control during ART has not been
studied. The existing literature suggests that CBT has been used to effectively improve
adherence to ART. Most of the interventions emphasized the use of cognitive strategies:
reframing maladaptive thinking about ART, improving coping skills, and confronting
concerns and beliefs about ART. Two studies (Ironson, et al., 2001; Molassiotis, et al., 2003)
demonstrated a statistically significant improvement in clinical endpoints (CD4 count and
viral load). The studies tended to be limited by small sample sizes (Jones, et al., 2003;
Molassiotis, et al., 2003; Parsons, et al., 2005), and the number of sessions, which numbered
from eight to 12 (Jones, et al., 2003; Molassiotis, et al., 2002; Molassiotis, et al., 2003;
Parsons, et al., 2005). In each of the latter three studies, attrition contributed to decreasing
sample size over the courses of each study (all of which ranged from three to six months).
Further this suggests that interventions that require many sessions with the therapist might
tend to lose patients—and thus, efficacy—over time.
The studies discussed suggest that CBT may help improve adherence to ART, but none of the
studies tested whether symptom control could be effectively achieved using CBT.
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Table 2.1 Studies of CBT in ART.
Study
Murphy, et
al (2002)

CBT
Intervention
Cognitive
therapy to
improve
self-efficacy

n

Design

Variables

Results

Implications

33

RCT

Adherence
by self
report

Higher selfefficacy in
intervention
group; NS
changes in
adherence

Authors suggest a
larger trial.

Selfefficacy
Molassiotis
et al (2003)

Education &
counseling
to maintain
adherence
to ART

12

One
group
repeated
measures

Adherence
by self
report

Intervention
increased
adherence
from baseline

Individualized
education and
counseling
improves
adherence to ART.

Jones, et al
(2003)

CBT to
improve
coping:
adherence
implications

174

RCT

Adherence
by self
report

Low-adhering
women had
less denialbased coping.
Intervention
improved
adherence in
this group.

Improvement in
coping may
improve
adherence.

Education in
side effect
symptoms

67

Hospital visits
for side
effects
decreased in
intervention
groups.

Education about
side effect
management may
reduce hospital
visits.

Chiou, et al
(2004)

Coping
strategies

RCT
3 arms

Self
esteem
Hospital
visits

Ironson, et
al (2005)

Self-efficacy
& HIV
disease
markers

56

RCT

Selfefficacy

Self-efficacy
correlated
with
improvement
in CD4 and
viral load;
reduced
distress in
CBT group.

CBT not targeted
directly at side
effects.

Parsons, et
al (2005)

CBT to
reduce
substance
abuse and
increase
adherence

12

One
group

Adherence
by self
report

Decrease in
substance
use
No changes
in adherence

Short, small n

RCT: randomized controlled trial. CBT: cognitive behavioral therapy. ART: antiretroviral
therapy. NS: non-significant.
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Furthermore, there was little use of behavioral techniques such as muscle relaxation.
The reports suggest that most of the interventions focused on cognitive techniques such as
education about ART.
Gaps in the Literature
Cognitive-behavioral therapies have been tested in patients with cancer, HIV, and
other diseases, both psychological and physical. The focus of this review has been on the use
of CBT to reduce symptom intensity and frequency in patients taking ART. In the first
section, six studies tend to suggest that adherence improves when a type of CBT is the
intervention, but the specific elements of CBT in each study varied. Thus, it is somewhat
difficult to draw conclusions about the most effective combination of techniques, which
include cognitive (educational, skill-building, coping, guided imagery, self-persuasion) and
behavioral (relaxation, distraction, behavior modification). However, when the literature on
CBT interventions in cancer care is included, some combination of education/reframing,
guided imagery, hypnosis, and relaxation emerge as preferred choices for designing an
intervention. In the studies of HIV and CBT, adherence generally improved, but no study
used side effect symptoms and adherence as a set of dependent variables.
Summary
Infection caused by HIV is life-threatening and persistent. Viral suppression is the
main goal of treatment, and leads to increases in CD4 counts and a reduction in opportunistic
infections and HIV-related mortality. Moreover, the HIV genome is highly mutable, leading
to the daily occurrence of drug-resistance mutations, which become more hazardous when
medications are taken inconsistently. Thus, ART must be continued definitely. Yet adherence
remains a problem. Forgetfulness, substance abuse and other behaviors may interfere with
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adherence. Side effects from medication—experienced, or simply feared—also interfere with
successful ART, whether because patients discontinue medications, or because their fears
prevent them from undertaking ART in the first place.
Adherence education has become a standard of care in the management of HIV
patients who consider taking, or who continue on, ART. Thorough, detailed instruction in the
use of medications, dosing, how to manage side effects, and other aspects of medication
taking has been shown to improve adherence. Psycho-educational interventions (e.g.,
counseling, individualized education) have also improved adherence in some studies, but not
in all studies. Whether psycho-educational interventions will improve adherence remains an
open question, and may depend on techniques that are used.
Side effects may interfere with medication taking, and this is also true in cancer
chemotherapy. A significant body of research supports the use of CBT in the management of
pain, anxiety, and nausea/ANV for such patients. The literature is silent on whether this
affects adherence to ANT, but such interventions definitely improve patient comfort and
sense of control. The literature contains four studies that looked specifically at whether CBT
or related psycho-educational interventions could improve adherence. Results suggest that
individualized CBT may improve adherence. Two studies were of such interventions, but
with self-efficacy/self-esteem (SE/SE) and hospital visits as the dependent variables, and in
general, improved SE/SE reduced hospital visits (assumed to correlate with disease severity)
and improved CD4 counts. No study looked specifically at whether CBT could be used, as it
has been in oncology, to reduce side effect symptom severity, and whether this would then
affect adherence in a positive way.
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Chapter 3
Methods
Research Design
This was a two group, randomized, controlled clinical trial. Both groups
(experimental, control) received the standard of care (SOC) (adherence education) from their
clinicians at their regularly-scheduled office visits. The experimental group also received the
intervention at three time points (I1, I2, I3). Three categories of measurement (symptom scores
by VAS, SF-36, and clinical laboratory data) were to be obtained at four time points. It was
planned that each participant in the control group would be measured at study entry and three
more time points, each about a month apart, until measurements were obtained for a threemonth period. Participants in the experimental groups would be measured at similar intervals,
with some allowances for scheduling with the behavioral interventionist, and each
measurement to be performed just prior to each of those three visits. The major advantage of
experimental design is its power to resolve research questions by active, prospective
comparison to controls, and thus to establish support for causality between the intervention
and the outcome. Limiting and/or controlling for confounders is another advantage of the
prospective design, and randomization contributes to that effort through the assignment of
attributes across both groups (Polit & Beck, 2004).
Setting
The study was performed in an academic medical center infectious disease clinic in
South-central Pennsylvania. The cognitive behavioral therapy (CBT) interventions were
delivered in a quiet conference room with low lighting and comfortable chairs. The setting
offered access to approximately 1200 HIV patients, 90% of whom were on ART at any given

46

time (J. Zurlo, personal communication, March 19, 2007). The center is part of the AIDS
Clinical Trials Group (ACTG) and is a federally funded HIV treatment center. The clinic
itself is also an outpatient cancer treatment center, with designated days during which
HIV/AIDS patients are scheduled.
Sample
Pre-trial discussion with the clinic’s physicians suggested that enrollment could be
significantly limited if random sampling was utilized; therefore, convenience sampling was
planned. The medical center’s institutional review (detailed further later) specified that
participants would be pre-screened by a clinic physician or nurse, and if the patient agreed,
the primary investigator (PI) could then explain the study in detail and offer the opportunity
to consent. It was planned that participants would be randomized to the experimental or
control group until the enrollment was filled. Rolling enrollment was to continue until 30
participants completed the study. Power analysis is described in a later section.
University- and institution-approved posters advertised the study. The PI attended
clinic each day that the nurse case manager (NCM) reported that there would be potential
participants available. (The clinic also mixed in many general infectious disease patients, so
some days no or few HIV patients were scheduled.) On occasion, clinic physicians also
notified the PI that a patient would be a suitable candidate for participation.
Eligibility Measures
The PI planned to recruit men and women, 18 years of age or older, who could read
and understand English, and who could give an informed consent. Participants on ART were
eligible if they affirmed that they suffered from one or more symptoms of nausea/vomiting,
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fatigue, pain, and/or anxiety related to side effects. Participants had to have been on ART
prior to study entry, but no minimum duration on ART was required.
A demographic questionnaire (Appendix A) was used to collect data to describe the
population and to determine eligibility requirements, and to confirm that participants were
actively symptomatic. Data were collected on age, race, education, and other attributes and
these were used to describe the population under study. Data on which of the four specific
symptoms participants suffered from were also collected.
Subjective Health Measures
Specific symptom measures. Visual analogue scaling (VAS) was selected to
quantify the four symptom variables (nausea, pain, fatigue, and anxiety). The four symptom
variables selected are based on the author’s clinical experience when faced with patients who
had or stated they would discontinue ART due to side effects.
Table 3.1
Symptom Variables
________________________________________________________________________





Nausea: to be understood as nausea, ―upset stomach,‖ or other unpleasant uppergastrointestinal sensations that the participant associates with medication use.
Pain: as felt by the participant; any pain is included.
Fatigue: to be understood as ―tiredness,‖ ―being wiped out,‖ or other terms, as felt by the
participant.
Anxiety: or ―a sense of worry,‖ ―dread,‖ or ―feeling nervous‖ insofar as it relates to
treatment or the disease itself (as it may be hard for participants to distinguish the two).

________________________________________________________________________

Visual analogue scaling was developed to measure patients’ experience of pain
(Keele, 1948). Subsequent refinements included the option of horizontal orientation and the
use of straight lines without numerical marks, and with the use of verbal descriptors at either
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end of the scale, reflecting the absence of a symptom to the perceived worst imaginable
experience of that symptom (Gift, 1989). Cline, Herman, Shaw, and Morton (1992) proposed
standardization of the VAS at 100mm, although other lengths have been proposed for other
purposes, such as measurement of ―absolute‖ pain and ―comparative‖ pain (Carlsson, 1983).
Wewers and Lowe (1990) reviewed how VAS has also been applied to the measurement of
nausea, vomiting, anxiety, mood, dyspnea, a host of other subjective complaints.
Reliability and validity of VAS. Visual analogue scales are reliable and valid.
Brunier and Graydon (1996) tested the reliability and validity of VAS against a Likert scale
in the measurement of fatigue. McCann and Boore (2000) used the 4-item vitality scale in the
SF-36 as a measurement of the opposite state of fatigue, and as a validity check on scoring of
the other measures in their study of fatigue in renal dialysis patients. In a study of general
fatigue and breathlessness in healthy volunteers (Grant et al., 1999), the VAS demonstrated
reproducibility coefficients of 78%, with correlations to physical demand measures ranging
from .73-.82. Lingjaerde and Føreland (1998) tested 162 patients with seasonal affective
disorder, and compared their VAS scales for global improvement after light-box therapy to
the Montogomery-Asberg Depression Rating Scale (MADRS) and a scale for atypical
depression symptoms (ATYP). Changes in VAS correlated closely with changes in MADRS
(r=.85) and moderately well with ATYP (r=.64). Test/retest reliability was .96 for two
consecutive ratings during a period in which participants reported no change. Muth, Stern,
Thayer, and Koch (1996) designed a nausea assessment profile and tested it against VAS in a
four-stage study involving over 1500 student volunteers. The purpose was to exhaustively
describe nausea as a sensation, test the scale in a group affected by motion sickness versus
control, and then to test correlation with VAS completed by participants. Correlation of .71
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with VAS was found. In pain measurement, De Conno et al. (1994) tested 53 patients with
cancer pain with 5 different rating scales, and a sixth at follow up after treatment of pain (to
evaluate change). The VAS and the numerical rating scale showed the strongest association
with absolute values of pain. Mottola (1993) suggests that VAS allows patients to render
continuous, subjective, abstract sensations into data without having to describe these
sensations in concrete terms. In this study, the VAS was used to measure nausea, fatigue,
pain, and anxiety. Participants were asked to rate these symptoms a total of four times. At
each time point a total of three scales were provided to allow the participants to rate three
dimensions of each variable. The VAS instrument used in the study is shown in Appendix B.
The anchors selected for the 4-week recall VAS were selected for their generality and their
extremity, as patients can be relied upon to render their general sense of how badly they have
felt or for how long in such terms (Gift, 1989). The 4-week recall was selected to coincide
with both the SF-36 and the interim between measurements.
In conclusion, high correlations with other types of scales and greater variability of
scores have been seen in other studies of the VAS (Guyatt, Townsend, Berman, & Keller,
1987; Price, Bush, Long, & Harkins, 1994; Winstead-Fry, 1998), furthermore, the VAS
seems to work well across various educable populations and for different symptoms (other
than pain, which has been best studied) (Borjeson et al., 1997; Folstein & Luria, 1973;
Guyatt, et al., 1987; Lee, Hicks, & Nino-Murcia, 1991; Winstead-Fry, 1998).
The VAS has been used in measuring symptoms in studies of persons with HIV.
Youle and Osio (Youle & Osio, 2007) utilized the VAS to measure pain in patients receiving
acetyl L-carnitine as a treatment for neuropathy. Reductions of pain in the intervention group
tended to be reflected in reductions in pain scores in both the McGill Pain Questionnaire and
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the Total Symptom Score instruments, although the authors did not report specific correlation
coefficients. Beal et al. (1995), in a study of the efficacy of dronabinol (Marinol®, Abbott
Park IL) for anorexia associated with weight loss in persons with HIV used the VAS to
measure appetite, mood, nausea, and vomiting. Fatigue was measured in HIV patients using
VAS in a comparison study of methylphenidate and pemoline lessening that symptom
(Breitbart, Rosenfeld, Kaim, & Funesti-Esch, 2001). The authors (Grant, et al., 1999) report
that the Piper Fatigue Scale (PFS) was used as the primary measure of the dependent variable
because it is well-validated. Changes in the Energy Subscale of the VAS for fatigue (VAS-F)
showed significant improvement along with the changes in the PFS. The VAS-F is 18 items
related to fatigue and energy, scored using VAS-type scales for each item (Lee, et al., 1991).
Sensitivity. The VAS is sensitive to changes in symptom experience. Ohnhaus and
Adler (1975), in a study of six subjects, compared the verbal rating scale (VRS) for pain to
the VAS. They concluded that the VAS had greater sensitivity to changes in pain after the
administration of pentazocine and attributed this sensitivity to the ―continuous‖ nature of the
VAS, allowing for finer discriminations to be made by subjects in reporting changes. A
similar study with similar findings using nausea as the dependent variable was undertaken by
Borjeson et al. (1997). Again, VAS demonstrated great sensitivity to change, with a change
in one step on a verbal category scale being associated with an average change of 20 mm on
0-100 mm scales for nausea intensity, with good agreement between verbal and VAS scales.
There are other instruments that are specifically designed to measure symptom scores
in persons with HIV. The HIV Assessment Tool was developed by Nokes, Wheeler, and
Kendrew (Nokes, Wheeler, & Kendrew, 1994) and tested in 60 persons with HIV infection,
43 with AIDS (defined by the Centers for Disease Control 1987 criteria), and 53 healthy
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controls. The tool performs well, with test-retest reliability of .96, Cronbach’s alpha of .92,
and good correlation with Karnofsky performance status (r = .51). Face, content, and
construct validity were also established. The 34-item scale uses VAS-type scaling, but does
not include questions specifically related to nausea, a symptom the author of the proposal
specifically seeks to measure. It also inquires about many symptoms that, if medication
related, suggest that a serious adverse event requires investigation and possible regimen
change (e.g., skin rash, skin sores, cough, bleeding, etc.).
The Sign and Symptom Checklist for persons with HIV disease (SSC-HIV)
(Holzemer et al., 1999) was expanded the number of symptoms and includes nausea as a
symptom. It also includes a variety of pain items by region (e.g., headaches, chest pain) as
well as a specific reference to ―fatigue‖ (as opposed to ―tiredness‖ in the HAT instrument).
The collected symptoms better describe the general discomforts often reported from ART
(e.g., gas, bloating) but still include many symptoms not under study here (e.g., wheezing,
chills). Moreover, the questionnaire is scaled ―mild-moderate-severe‖ and thus loses the
continuous scalability of scoring available with VAS.
General health measures. The SF-36 was developed to measure a range of health
outcomes by Ware and Shelbourne (1992), for the Medical Outcomes Study (MOS), a multiyear research project designed to study patients with chronic conditions (Tarlov et al., 1989).
The SF-36 is a self-administered instrument designed to measure interlocking domains. The
SF-36 measures limitations of physical activities, pain, general mental health, limitations of
usual role activities, vitality, and perceptions of general health (Ware & Sherbourne, 1992).
It should be noted that shorter forms related to multidimensional outcomes
measurement do exist (e.g., Short Form-18, Short Form-20 [SF-20], SF-30-HIV), and indeed
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such instruments are arguably more efficient to administer and would perhaps be easier to
complete by study participants. However, Ware and Shelbourne (1992) present data that
supports their assertion that some precision is lost in the use of the shorter scales, and that the
somewhat longer SF-36 captures more real world types of limitations in function. For
example, the SF-20 only offers one social functioning item. The developers found that adding
a second item increased content validity for this sub-domain of overall function (Ware &
Sherbourne, 1992). The developers also felt that the SF-20 did not adequately capture
dimensions of health and function as these pertain to energy, lack of tiredness and similar
concepts, and so added a vitality subscale. This addition was based on data from the National
Health and Nutrition Examination Surveys (Stewart & Ware, 1991).
The SF-36 is well-validated, reliable, and is normalized to the general United States
population (Hays, Sherbourne, & Mazel, 1995; McHorney, Ware, Lu, & Sherbourne, 1994;
McHorney, Ware, & Raczek, 1993; Stewart & Ware, 1991; Ware, 1987). The use of the SF36 in the proposed study of HIV patients on ART would provide another set of measurements
to compare to those VAS scores for specific symptoms (pain, fatigue, etc.) and provide
numerical data on other quality of life dimensions, such as vitality, function, role, and
emotion. There is one item on the SF-36 that asks if the respondent feels his/her health is
better, worse, or unchanged from one year ago. This reflects the customary use of such
instruments in longer-term studies such as the MOS. However, subsequent developments in
the SF-36 have led to the production and testing of versions that allow for shorter terms of
recall, and thus shorter intervals of change (Ware, 2005). The SF-36 was administered at each
of the four time points described, and takes approximately 10 minutes to complete.
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Table 3.2
Explanation of the SF-36 Scoring System
Concepts

# of
# of
Items Levels

Reported Health
Transition (HT)

1

5

Physical
Functioning (PF)

10

21

Role--Physical
(RP)

4

5

Bodily Pain (BP)

2

11

General Health
(GH)

5

21

Vitality (VT)

4

21

Social
Functioning (SF)

2

9

Role—Emotional
(RE)

3

4

Mental Health
(MH)

5

26

Meaning of Scores
Low
Believes health is much
better than a year ago.
Limited in performing
physical maintenance.
Conceptually related to
―ADLs‖ (activities of daily
living).
Problems with work or
other activities.
Conceptually related to
―IADLs‖ (instrumental
ADLs).
Severe, limiting pain
Evaluates health as poor
and believes it will get
worse.
Feels tired and worn out
all the time.
Physical and/or
emotional problems
severely interfere with
social activities
Problems with work or
other daily activities
resulting from emotional
problems.
Feelings of nervousness
and depression all of the
time.

High
Believes health is much
worse than a year ago.
Performs such activities—
even the most vigorous—
without limits due to
health.
No problems with work
etc. related to physical
health.
No pain or limitations due
to pain.
Evaluates health as
excellent.
Feels full of pep and
energy all of the time.
Normal social activities
without interference.
No problems with work or
other daily activities
resulting from emotional
problems.
Feels peaceful, happy,
and calm all of the time.

Note. ―Items‖ refers to the actual instrument questions, of which there are 36 and ―levels‖
refers to the number of items that contribute to that domain score. There are eight domains, as
described above, and one ―health transition‖ score.
Adherence Measures
This study also used a VAS for participant estimates of average adherence over the
past month (Walsh, Mandalia, & Gazzard, 2002), as well as 3-day recall (Chesney et al.,
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2000; Giordano, Guzman, Clark, Charlebois, & Bangsberg, 2004). The instrument designed
by Chesney, et al. was structured, complex, and also inquired about specific reason for
missing medication doses, and other data. Oyugi et al. (2004) employed the 3-day recall in its
more common form: doses prescribed and doses taken over the last three days. That is how
the instrument was used in this study.
There are several measures of adherence that have been explored for use in research
studies including biological assays of drug levels or for drug metabolites, pill counts, selfmonitoring/self-report, clinician estimates (Dunbar, 1980; Murri et al., 2004), electronic
monitors (Diaz et al., 2001; R Gross, Bilker, Friedman, & Strom, 2001; Hinkin et al., 2002),
and interviews, which may or may not include the use of scales (such as VAS, numerical
rating scales, etc.) (Holzemer, et al., 1999; McPherson-Baker, et al., 2000).
Electronic monitoring is expensive (AARDEX_Group, 2007; Lamb, n.d.) and
correlations with patient self-report is fairly good, (Melbourne et al., 1999) although patients
tended to report a few percent higher adherence in the study by Melbourne et al.
Unannounced pill counts (UPC) can be used, and are a less expensive measure of
adherence. In a study that compared 3-day recall UPC and a VAS for adherence Giordano,
Guzman, Clark, Charlebois, and Bangsberg (2004) found that the correlation between VAS
and UPC was high (r=.76) and the difference between VAS and 3-day recall was nonsignificant. Moreover, there was a trend toward inverse correlation between data from VAS
and viral load measurements (r=-.49, p<.30), suggesting that participants who were taking
their medications regularly and on time also tended to have better suppressed virus. Walsh,
Mandalia, and Gazzard (2002) VAS adherence data correlated strongly with MEMS Caps
data (r=.63, p<.001), pill counts (r=.75, p<.001), and an author-designed adherence
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inventory. Again, VAS was inversely correlated with viral load. This study uses a single VAS
to measure medication recall ―since your last visit,‖ as it can be argued that this reflects realworld adherence monitoring. Adherence was measured four times at T 1, T2, T3, and T4.
Adherence scores by VAS were rated on a 100mm scale. A score of 100 equates with
reported perfect adherence. In this study the data from the 3-day recall was converted to an
index:

Doses taken
------------------------------- = x
Doses scheduled
Thus x becomes a number between 0 and 1, and represents a percentage. For example a result
of 0.5 meant half the doses were taken.
Control Measures
The use of side effect reducing medication (SERM) was measured, as it was
considered a potential confounding variable. It was not hypothesized that participants in the
intervention group will use less such medication than controls. Measuring the use of such
medication would allow for statistical control of this variable in the analysis. A flow-sheet
style diary (see Appendix C) was included in the measurement tools given to each
participant. The diaries were designed to cover the approximately one-month span between
each of the four measurements. Thus, each participant had to turn in three diaries.
Participants were asked to record their use of various SERM, for nausea, pain, and anxiety.
Participants were instructed that over-the-counter and prescription drugs were to be included,
and they were told they did not need to specify which drugs they used. Drugs for fatigue were
not included in the diary, because there are no drugs approved for the treatment of fatigue as
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a symptom, by the U.S. Food and Drug Administration. The measure was intended to capture
only the number of doses being consumed for the other three symptoms.
Immunologic Measures
Viral load. This study used viral load data from chart reviews. Recommendations for
the management of stable HIV patients call for testing serum virus levels and CD4
lymphocyte counts every three months (Panel_on_Antiretroviral_Guidelines_for_Adults_
and_Adolescents, 2009). These data were to be collected at two time points including
baseline, (T1, no more than one month prior to or after starting the study), and at the end (T 4,
within two weeks before or up to one month after a given participant’s completion). Although
there was one research site, due to insurance requirements for individual participants, some
participants had to obtain their tests from other laboratories. Because of this measurement
variance from laboratory to laboratory variance was a concern. With advances in both
technology and regulation this concern was believed to be less of a confounder than in the
past. The planned timing of laboratory studies was discussed with the study site lead
physician.
Patients’ viral loads were expected to be reported from either branched-chain DNA
(bDNA) assay or by polymerase chain reaction (PCR) assay. Branched chain DNA assay, a
variant of PCR, might be more sensitive to low levels of virus, less dependent on taxonomy,
and exhibit less error than PCR of the reverse-transcriptase gene (RT-PCR) (Grimes et al.,
2003). Today, bDNA and RT-PCR achieve detection of virus down to less than 10
copies/mL, although commercial assays with detection limits from <200 copies/mL to <25
copies/mL are more common, with the preponderance of laboratories providing detection
limits on the lower end of that range. Detection limits are further discussed in Chapter 4.
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Interlaboratory variation regionally. Regional variance in viral load testing was
studied (Kellogg, Atria, Sanders, & Eyster, 2001). In that central Pennsylvania population,
the authors were able to conclude that changes in measured virus levels less than 0.50 log10
were likely due to testing variation. Changes equal to or greater than 1.00

log10

are considered

to be clinically significant. Inter-laboratory variance was considered as a potential problem,
and the findings related to such variation are discussed further in Chapter 4.
Regulatory controls on variation. The Clinical Laboratories Improvement Act
(CLIA) of 1988 provided a legal basis for the enforcement of compliance and competency
standards in clinical laboratory testing. Although the U.S. Center for Medicare and Medicaid
Services (CMS) has monitoring and enforcement jurisdiction over laboratory testing, thirdparty accreditation agencies normally conduct routine evaluation of competency and
compliance (CMS, 2006). (The College of American Pathologists [CAP] and Joint
Commission for Accreditation of Healthcare Organizations [JCAHO] are two of the major
accreditation agencies in this regard [N. Sheaffer, personal communication, December 7,
2006.]) All of the laboratories that participants might use would be subject to CLIA, and this
fact provided a modicum of certainty that interlaboratory variation would be minimized.
CD4+ lymphocyte (CD4) count. This study used CD4 counts from chart reviews at
T1 and T4., and—since these are usually drawn together—the same timing criteria discussed
in the section on viral load. Concerns about variation among laboratories applied here as
well. ―Single platform‖ flow cytometry (FC) analysis has recently become a more common
means of measuring CD4 counts. Such systems have used cell-sized, fluorescent-tagged
beads of fixed amounts as controls added to the FC sample, enabling an actual counting of all
signals (C. Boyer, personal communication, December 7, 2006; Beckton, Dickinson, &
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Company, 2003). Single-platform testing has been shown to be a more accurate measure of
absolute THC in whole blood (O'Gorman & Nicholson, 2000). The laboratories used in this
study are CLIA-certified (C. Boyer). Against the standard calibration standards no more than
2% variance is likely. Laboratories in each geographic location each tested a sample with a
CD4 count of 100, the widest potential variance between their results would be 98-102
cells/mm3 (N. Sheaffer, personal communication, December 7, 2006).
Standard of Care and Experimental Intervention
The standard of care (SOC): adherence education. The importance of adherence
and recommendations for adherence training were established in Chapter 2. The SOC for this
study is ―usual care,‖ which is described in this section.
During the practical coursework prior to the proposed study, from February to April
2006, this PI conducted observations of clinical encounters at the treatment sites that were
approached for the present study. All clinics were Ryan White-funded entities. Two of the
fours clinics were hospital affiliated, one was a satellite site of a major academic medical
center, and one a private, non-profit clinic.
During the observation period, the author recorded notes on 10 visit encounters for
HIV care. The clinicians providing adherence assessment and education were two physicians,
three nurse practitioners (NP), a registered nurse (RN) and a pharmacist. This group is
reasonably believed to constitute a representation of the ―average‖ specialist clinician treating
HIV patients.
Three types of occasions for adherence education were observed. The first occasion
for education is when planning to start a regimen. This may include discussions in visits prior
to the actual prescription. The second occasion is at follow up, to monitor adherence and
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repair any problems. The third is when a regimen is changed (all or part). Adherence
education was more formalized for the new patient, or for the patient facing a significant
regimen change. For patients already on ART for some time (months, years), the assessments
focused on most of the major areas discussed by Golin et al. (2004), but with less emphasis
on touching each point outlined by that group. The assessments tended to follow a model
similar to that used in medical history taking, for example: clinicians often asked a screening
question such as ―Are you taking all of your meds ok?‖ Any equivocation would prompt
further questions, e.g.: ―Are you taking your Combivir with food?‖ or ―Is it the taste of the
Norvir that’s keeping you from taking it?‖ and so on, until a ―diagnosis‖ of the adherence
issue was established.
During the observations, clinicians missed some features of adherence education
outlined by Golin, et al. (2004) in some visits. The assessment of adherence was sometimes
approached in very different ways by different clinicians. This observation was recorded in
all the regional clinics examined. Since both the control group and the experimental group
will continue visiting their clinicians as scheduled, this SOC will be common to both groups.
The independent variable: the intervention protocol. The intervention consisted of
three CBT sessions. The first session was designed to impart the basic therapeutic thrust of
CBT which includes using thoughts to frame the experience and reinforce an internal sense—
or locus—of control (A. T. Beck, 1976; J. S. Beck, 1995; Kalichman, 1995), and to discuss
individual participant concerns, symptoms, etc. The cognitive piece of CBT was focused on
assessing those concerns, and on working with the patient to establish a knowledge base
about the purpose of the encounters. This teaching did not focus on knowledge about ART.
That had already been done by the treating clinician, nurse, or pharmacist in a medical
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setting. Rather, the purpose of this encounter was to inquire about perceived psychosocial
limitations, how symptoms were being experienced, and their meaning to participants.
Perceived limits to adherence, anxiety about medication taking, and other treatment-related
issues were primary (K. Bakke-Friedland, personal communication, April 21, 2006). The
session content is detailed in the following sections. Participants received reminders about
appointments with the behavioral interventionist (BI) by telephone call to a number of their
choice. The PI made all such contacts.
Timing of the first session. In participants assigned to the experimental group this
first visit was planned to occur within two weeks of assignment. This was to allow for
scheduling that would be convenient to participants, but assure that they also moved along at
the same pace in the study as those participants in the control group.
Detail: the first visit. This was an introductory session. The items below were
interspersed throughout the session, but are listed below in their approximate order of address
within the session:


CBT, its relevance to adherence.



Introduction, and getting to know the participant, 10 minutes



Self-defeating thinking, 12 minutes



How automatic thoughts affect our mood and behaviors, 12 minutes



Participant personal sharing, 10 minutes



Plan for following sessions, 6 minutes
Timing of the second session. The second visit was scheduled about three to four

weeks after the first session.
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Detail: the second visit. This was designed to begin to implement the CBT strategies.
Format was similar.


Review and update with the participant by the behavioral interventionist (BI), 10
minutes



Introduction to progressive muscle relaxation (PMRT), 10 minutes



Coached session of PMRT, 15 minutes, (recorded)



Questions and personal sharing, 10 minutes



Plans for next session, 5 minutes
The PMRT session was recorded, and each participant was given a compact disk

(CD) with the session for use in private practice sessions at home or elsewhere. No
restrictions were placed on how often or where they could listen and practice. It was
suggested they use the practice CD daily or at least several times a week.
Progressive muscle relaxation training. This involves the coached tensing and
relaxation of groups of muscles. The tensing helps focus the person’s attention to the area.
The person is then coached to relax the muscles just tensed. The original procedure could
require 30-45 minutes (Bernstein & Borkovec, 1973). Later variations have been adapted to
require as little as a few moments to several minutes to 20 minutes or more (Schweitzer &
Miller, 2005). Bernstein and Borkovec offer very clear guidelines for PMRT. The present
study modified these conditions. In this study we used the ―seven muscle group‖ procedure
(Bernstein & Borkovec, 1973, Chapter 7), as this was felt to provide a reasonably thorough
session while preserving time. It requires 10-12 minutes. It was judged that participants
should to be able to use PMRT as often as necessary, and that brevity could contribute to
more frequent use. No literature was found that contradicted such an assumption.
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Timing of the third session. The third session followed the second session by about
three to four weeks.
Detail: the third session. This was designed to move the control of the techniques to
the participant, review and follow up on any issues during the interim.


Review and update with the participant by the BI, 10 minutes



Introduction to guided imagery (GI), and exploration of participant imagery models,
10 minutes



Coached session of GI, 15 minutes



Disengagement, 15 minutes
Guided imagery. GI is a technique in CBT, and is the use of live coaching to help

patients develop assistive, positive, or otherwise motivational imagery. Alternatively, the
imagery may be relaxing and anxiety-relieving, or may be intended to force vicarious contact
with feared events for the purpose of confronting unpleasant thoughts and then reframing
them. The coaching of imagery is inspired in its development by the patient and how he
symbolizes his world, but is guided by the therapist (J. S. Beck, 1995).
Although effect sizes are moderate (.50), PMRT and GI have been found to be
effective in the management of similar symptom clusters (nausea, anxiety, etc.) associated
with antineoplastic therapy (Burish, et al., 1987; Burish & Tope, 1992; Carey & Burish,
1987; Simonton, Matthews-Simonton, & Sparks, 1980), and were believed to be reasonable
choices to begin exploring CBT in patients with HIV who are undergoing ART.
Duration and Personnel
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All sessions were scheduled for 50 minutes, the industry-standard counseling session
(Kathrine Bakke-Friedman, personal communication, June 16, 2006). All CBT intervention
sessions were administered by a Pennsylvania-licensed psychologist.
Safety Issues Relative to CBT
During CBT sessions, it was considered possible that some participants might
experience psychic discomforts related to specific concerns, and could include:


Expressions of suicidal ideation



Expressions of harm toward others



Hallucinations, other manifestations of psychosis



Unpleasant memories of suppressed events such as rape, battery, other forms of abuse



Undiscovered psychological pathology that emerges during training sessions



Any behavior, expression, or other event that, in the opinion of the therapist, should
prompt an evaluation, as detailed in the next paragraph
Such events would prompt the primary investigator (PI) and the BI to discuss

disposition of such participants. The plan for such events was that participants would be
offered referral to inpatient or outpatient services, as appropriate, based on the clinical
judgment of the team, in consultation with the participant’s treating clinician. Participants
were advised prior to entry that such referral was not part of the study would be pursued
within their ordinary treatment channels. (All patients of Ryan White-funded HIV services
are covered in some way for such professional services for mental health. This does not rely
on specific insurance plans, although such plans may be used to pay for mental health
services.) All study participants were evaluated by the PI prior to entry for access to mental
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health services. Participants were advised that they could withdraw at any time without
penalty.
Other issues that could come to the attention of the PI or research team and demand
reconsideration of further participation included:


Hospitalization for opportunistic infection or other cause (e.g., myocardial infarction):
termination of participation: if hospitalization would exceed one week



Any opportunistic infection not requiring hospitalization (additional burden of
medications or procedure may make orderly follow up impossible): re-evaluation of
participation



Symptoms such that a participant withdraws from ART: termination of participation



Relapse of substance abuse behavior that interferes with participation in study visits
termination of participation if behavior is associated with missing any study visit
Brief hospital stays, a single episode of substance abuse followed by renewed

abstention, or other relatively minor events were not considered to be reasons to discontinue
participation, if he/she wished to continue. Antiretroviral therapy is often continued in such
circumstances. It was reasonable to consider that the CBT intervention could even contribute
to continued use of ART by patients experiencing such short term difficulties.
Procedures for Data Collection
After consent and randomization, each participant was provided with the first set of
measurement tools and allowed time to complete them while waiting during the medical visit.
In a few cases, time constraints made it necessary for the participant to complete and return
the measurement tools to the researcher via a self-addressed, postage paid envelope. In all
cases, participants were provided with verbal instructions read from the instrument. The
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instructions were also available for the participant to read later if needed. Participants in the
control group were asked to complete and return the measurement tools at specific time
points. Thus, two or three sets of measurement tools were given to the control group
participants after informed consent was obtained.
Each set of measurement tools included a symptom VAS, an SF-36, and an adherence
tool (both VAS and 3-day recall). A SERM diary was also include in each set. Each tool, in
addition to including instructions on use, was individually marked with the participant
number, the measurement number, and the date completed. Sets of measurement tools given
to the control group participants for completion at end of 30-, 60-, and 90-days, were further
marked with the specific dates to be completed. In addition, each set of tools was color coded
using tinted paper, to provide further clarity. Participants in the experimental group also
received calendars with instructions on how to record practice sessions of PMRT (for
measurements T3 through T4). However, these were not provided until they had actually
attended the second session, and were individually dated for each participant. As a rule, all
instruments’ instructions were discussed with participants.
There were four planned measurement events. The planned timing is shown in the
scheme in Figure 3.1. In planning, it was believed that scheduling could conform somewhat
closely to this scheme. In practice, these times were difficult to adhere to. More on this is
discussed in later chapters. As was noted, telephone reminders were used frequently, both to
remind control group participants to complete their measurements, and to remind
experimental group participants to attend their meetings with the BI, as well as to remind
them to complete their final surveys.
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Participants entering the study were measured at T1, study entry, and then again at T 2
(1 month into the subject’s participation in the study), T 3 (two months into the study) and T4
(three months into the study, at its end). The measurements in the experimental group were to
be timed similarly, although getting measurements before the intervention visit, even
immediately before, was considered paramount, as it was believed that measurements
immediately after the intervention visit would be artificially improved (lower symptom
scores, higher SF-36 scores) because of ―priming‖ recollections with a recent pleasant
experience (the intervention visit). The data collection plan is shown in Table 3.2.

Figure 3.1 Study Scheme.

CONTROL
Accrual &
Consent

T2

T1

Randomization

T3

I3

I2

I1

T4

EXPERIMENTAL

Month 0

1

2

3

Notes: T1: Time 1 (study start); T2: Time 2 (1 month); T3: Time 3 (2 months); T4
Time 4 (study exit). I1: Intervention 1 (scheduled within 2-4 weeks of study start); I2:
Intervention 2 (scheduled 2-4 weeks after first intervention); I3: Intervention 3
(scheduled 2-4 weeks after second intervention).
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Table 3.3
Data Collection Plan
Study Start
(Time 1)
Group
C
E
Measures VAS
VAS
SF36
SF36

CD4
VL
How
collected

1 Month
(Time 2)
C
E
VAS
VAS
SF36
SF36
SERM SERM
PRAC

2 Months
(Time 3)
C
E
VAS
VAS
SF36
SF36
SERM SERM
PRAC

CD4
VL

In
In
person person

Mail

In person
(Before
session)

Mail

In person
(Before
session)

Study Exit
(Time 4)
C
E
VAS
VAS
SF36
SF36
SERM SERM
PRAC
CD4
CD4
VL
VL
Mail

Mail

Note. C = control group; E = experimental group; VAS = visual analogue scales for nausea,
pain, fatigue, anxiety; SF36 = Short Form-36; SERM = side-effect reducing medication diary
sheet; PRAC = practice diary calendar; CD4 = lymphocyte counts; and, VL = serum virus
level.
Ethical Considerations
Approvals. Institutional Review Board (IRB) approval was obtained from Duquesne
University and from Penn State University College of Medicine (Hershey, PA). Informed
consent (Appendix D, approved by both IRBs) was presented to subjects after they expressed
an interest in the study but before randomization. Participants and clinicians were reminded
that changes in medical regimens as deemed necessary, as well as the use of SERM, should
proceed as they normally would, and was believed would reflect real-world demands of ART
as well as supports participants’ safety. The consent form was explained to each participant,
and each was given ample time to read the form. The investigator completed National
Institutes of Health Human Subjects Protection Education for Research Teams on February 6,
2004, on file with Duquesne University School of Nursing. Penn State employs a proprietary
computer-based tutorial that concerns human subjects’ protection, and this was completed by
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the PI as part of the IRB approval process at that institution, and is on file with the Human
Subjects Protection Office in the College of Medicine.
Health Insurance Portability and Accountability Act (HIPAA) and data security.
Approvals for information security were obtained during the Duquesne University IRB
approval process. At the beginning of their participation individuals were assigned a code
number, sequentially generated from ―01‖. All materials related to the participant, such as
mailed surveys, displayed only that number, and no name. Data files displayed the number
only. The only place names and numbers appeared together on any document or file was in
the data folders, kept in a locked cabinet at the PI’s university office. The number was
generated at the same time as informed consent was obtained and followed each participant
throughout the study. Once used, numbers were discarded if a participant left the study; thus
all numbers were unique.
Initially, mail communications were thought to be a potential security concern (since
a name would be on each envelope); however, all participants agreed to receive mail
communications and did not express any special concern about that. Efforts were made to
avoid using terms like ―HIV‖ ―AIDS‖ or ―antiretroviral‖ on any printed materials (such as
measurement instruments) and in phone messages/reminders.
A ―master list‖ in Microsoft Excel contained no reference to the terms ―HIV,‖
―CD4,‖ or any other health information, and served to link numbers with names, progress in
the study, and other tracking information. This was necessary to maintain the study, and the
data were kept on removable a removable medium, not part of a laptop hard drive, and kept
with the data folders, as well. The BI completed a confidentiality agreement (Appendix E).
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All identifiable data including raw data files and consents was destroyed at the end of the
study (approval of dissertation and final filing of electronic dissertation).
Payment to participants. Participants were paid $10 for each set of surveys
completed, to help defray costs of transportation, childcare or other inconvenience. Payment
was the same regardless of whether a participant was in the control or experimental group.
Cash was paid during in-person encounters. Checks were issued from a private account for
mailed surveys.
Data Analysis
The independent variable under study is the introduction of the experimental
intervention. The dependent variables are summarized in Table 3.3. These include potential
confounding variables. Descriptive statistics were performed, and the groups examined at T 1
for equivalence. The data were also examined for normal distribution of scores and variances
between groups.
Statistical tests. The study examined three hypotheses, one directional and two nondirectional, and also considered an array of potential confounders or covariances (e.g., SERM
use). The intervention and measurements was planned to occur over three months. Multiple
analysis of variance (MANOVA) and repeated measures analysis of variance (RM-ANOVA)
were considered, as these would account for between-group differences, within-group
differences over time, and the effects of variables on one another, as well as reduce the
likelihood of Type I error. Use of these tests, however, depends on the data meeting criteria
for parametric testing and would have required a very large sample size (Field, 2009, P.
Ricci, personal communication, September 11, 2009). A study designed as a proof-ofconcept trial would not submit to these tests, given the small sample size. In addition, Polit
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and Beck (2004) and Field (2009) argue that multiple ANOVAs do not truly test the effects
of multiple variables among groups, they merely repeat the same analysis with different
Table 3.4
Dependent and Control Variables
Variable &
number of dimensions

Measure and Scale

Analysis of

Nausea 3 dimensions

VAS 0-100 mm

Primary hypothesis

Pain 3 dimensions

VAS 0-100 mm

Primary hypothesis

Fatigue 3 dimensions

VAS 0-100 mm

Primary hypothesis

Anxiety 3 dimensions

VAS 0-100 mm

Primary hypothesis

Physical Function

SF-36 0-100 normative

Primary hypothesis

Role Physical

SF-36 0-100 normative

Primary hypothesis

Bodily Pain

SF-36 0-100 normative

Primary hypothesis

General Health

SF-36 0-100 normative

Primary hypothesis

Vitality

SF-36 0-100 normative

Primary hypothesis

Social Function

SF-36 0-100 normative

Primary hypothesis

Role Emotion

SF-36 0-100 normative

Primary hypothesis

Mental Health

SF-36 0-100 normative

Primary hypothesis

Adherence

VAS 0-100 mm

Primary hypothesis

Adherence

3-day recall

Primary hypothesis

Doses taken/Doses
Prescribed
Viral load

Log 10

Primary hypothesis

CD4

Absolute count

Primary hypothesis

Doses of SERM

Days in period/Doses taken

Control variable

(Arithmetic average)
Times CBT practices

number of participant-

Control variable

initiated practice CBT
sessions

Note: VAS = visual analogue scales for nausea, pain, fatigue, anxiety; SF36 = Short Form36; SERM = side-effect reducing medication diary sheet; CD4: lymphocyte counts; the
number of dimensions includes a VAS for each of level of the symptom in general, the worst
experience of that symptom, and the average duration of the symptom, over the prior month.
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factors without the ability to examine the effect of simultaneity that actually does occur with
multiple independent variables (e.g., our ―control variables‖, participant attributes). Doublymultivariate analysis is another method to test several related, dependent measures, repeated
at fixed time points. However, the number of dependent variables cannot exceed the number
of participants in that method (P. Ricci, personal communication, September 14, 2009),
which was the case in this study. Parametric testing rests on assumptions of independence,
equal variances, and normality of scores. Because these could not be assumed until the data
were actually analyzed, post hoc, non-parametric testing was also planned.
Hypotheses of extent of change. This study hypothesized that changes (effect sizes)
would be at least one standard deviation (SD) of 20 mm on the VAS. Various ranges of effect
size for various psychological interventions in oncology symptom management are .17 to .64
(Meyer & Mark, 1995), and .31 to .49 (Tatrow & Montgomery, 2006). An effect size of .50
could be expected. However, in other studies limited to using VAS as a measurement tool,
effects sizes were much larger, perhaps because of the sensitivity of VAS to changes in
symptom levels (Gift, 1989; Grant, et al., 1999). Several such studies are summarized in the
next paragraph. A change of 20mm (20%) has been considered a clinically significant change
in other studies (Nusstein, Steinkruger, Reader, Beck, & Weaver, 2006; Syrjala, Donaldson,
Davis, Kippes, & Carr, 1995; Wang, Belza, Thompson, Whitney, & Bennett, 2006),
Power analysis. The study proposed to enroll 15 per study group.
Using the formula:
1 - 2
ES = -----------
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Using a hypothetical average score of 50 mm, the experimental change would be assumed as
a mean of 30 mm.
50 - 30
ES = -----------
20
1.00 = -----------20
Using an effect size of 1.00 we can calculate that 15 participants in each group would provide
a power of .80. The study aimed to recruit 15 participants for each group (K. Kjelrulff,
personal communication, July 3, 2007; Lenth, 2006; Lipsey, 1990)
Level of significance. One-tailed testing with the significance level set at .05 was
planned for the first, directional hypothesis concerning VAS symptom scores and SF-36
scores, and two tailed testing was selected for the non-directional hypotheses concerning
adherence and CD4 counts/viral loads. The use of a level of .05 is a common level of
significance for studies of psychobehavioral interventions in nursing and psychology studies
(Polit & Beck, 2004).
Software. The analysis used version 16.0.1 of SPSSTM for the overall analysis.
Scoring for the SF-36 was done on Microsoft Excel 2007 TM, with author-programmed
formulae based on the scoring algorithms in Ware, Kosinski, & Gandek (2005).
Summary
This was a randomized, controlled clinical trial that planned to recruit 30 participants
(approximately 15 in each arm). Each group of HIV-infected participants would receive the
standard of care (adherence education). The experimental group would meet with the BI, who
would deliver three sessions of CBT with an emphasis on participant-practicable techniques
such as PMRT and GI, chosen for their demonstrated ability to reduce arousal, and shift locus
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of control internally. This was done to examine whether or not experimental group
participants would score lower on VAS of nausea, pain, fatigue, and anxiety, and whether the
intervention would have any effect on adherence, CD4 or viral load. Males and females 18 or
older were recruited from an infectious disease clinic. Participants had to be on ART for any
duration, and to have one or more of the symptoms being measured. In addition, general
health measures, adherence to medications, SERM use, and laboratory data were to be
collected at four time points over three months. Planned analyses included repeated measures
ANOVA, with non-parametric testing used for the post hoc analyses.
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Chapter 4
Results and Data Analysis
This chapter reports the findings, and begins with a report of the sample that was
recruited. The final sample is described and the composition of the experimental and groups
follows. The statistical analysis is introduced. Finally, the results and analysis of data are
organized according to hypotheses tested.
Recruitment and Study Completion
Recruitment took place over an eight month period from September 16, 2008 to June
1, 2009. The target enrollment was 30, with an estimated number per group of 15. Final
enrollment was 33, with 9 in each group completing the study. During the recruitment period,
384 individuals were screened by clinic staff, and 57 were approved for recruitment. This
captured 15% of the clinic attendance. Of these, 33 agreed to participate. No specific data
were collected on why potential participants declined participation but the most common
reasons noted were disinterest and/or lack of symptoms. Table 4.1 displays details about the
participants as they progressed to the end of the study. A total of 18 (55%) of the enrolled
participants completed the study; 15 or 45% of those enrolled did not complete the study.
Participation of those listed as ―Suspended‖ was finally discontinued by the investigator
because the intervention became unavailable due to the loss of the behavioral interventionist.
This was because of unexpected and personal reasons.
No data were collected on why participants left the study, beyond the reasons stated in Table
4.1. Participants lost to follow-up (LTF) were contacted more than eight times on average,
and generally for 30 days before no further contact was attempted. In most cases, the staff
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was unable to supply any additional information on why such participants could not be
contacted.
Table 4.1
Summary of Enrollees and Withdrawals
Group

N enrolled

N completing

Control

12

9

% Completing

Reasons for
Leaving the Study
LTF 3

75

Experimental

21

9

42

Total

33

18

55

LTF 3
Scheduling
problems 2
Medical 2
Died 1
Incarcerated 1
Suspended 3*
15

Note. *Suspended when the enrollment was halted. LTF = lost to follow-up.

Figure 4.1 Summary of Recruitment and Retention
Number of
clinic patients
screened by
staff

Number of
clinic patients
approached
for recruitment

Number of
patients
consented to
study

384

57

33 (58%)

Number of
participants
who
completed the
study
18 (55%)

Not
consenting
24 (42%)

76

Not
completing
24 (45%)

Description of the Sample
Participants who completed the study are described in Tables 4.2 and 4.3. The sample
was predominantly Caucasian males, with the exception of one Caucasian female participant.
Experimental designs assume that randomization will produce groups that are comparable.
This study used a randomized design until 29 participants were enrolled. At this time losses
to follow-up already approached approximately 27% (attempts to contact recent lost
participants were continuing), and assignment was changed to a stratified randomized design.
The remaining four enrollees were all assigned to the experimental group, however none
completed the study and thus, by default, a true randomized design was preserved in the final
data set. A t-test of between group differences at baseline suggests that the groups were not
significantly different. The majority of participants were white males.

Table 4.2
Demographic Composition of the Sample
Frequency Percent
Male

17

94.4

Female

1

5.6

Caucasian

15

83.3

Caucasian Hispanic

1

5.6

African American

2

11.1
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Table 4.3
Descriptive Statistics of the Total Sample (N=18).
N Range Min. Max.

Mean

SD

Variance

Skewness*
Statistic

Std.
Error

Age in years

18

16

40

56

46.8

4.2

17.4

.67

.54

ART # of
Weeks

18

467

13

480

200.2

160.5

25772.5

.58

.54

Starting CD4

13

1241

121 1362

544.2

352.2 124069.5

1.10

.62

Starting VL

18

147

0

147

58.6

42.9

1838.9

-.038

.54

Start
Log10VL

18

2.2

0.0

2.2

1.4

.9

.79

-1.05

.54

Valid N

18

Note. SD: standard deviation. ART: antiretroviral therapy. CD4: CD4 lymphocyte absolute
count. VL: viral load. Log10VL: VL in log10. *Rounded to nearest .01.
Completeness of data. The demographic data were 100% complete. More than 90%
of the surveys were completed and returned. Of the surveys that were collected >95% of the
items were completed; that is, the VASs (symptom scores and adherence), and the items on
the SF-36. About 85% of the SERM-use diaries were returned, many blank, and blank diaries
were counted as ―no SERM used.‖ Complete sets of laboratory data were missing on all with
the exception of six participants, and many had neither beginning nor ending reports. The
most common reason for missing laboratory data was that the participant had not reported to
a laboratory for the sample to be drawn. The second most common reason (only two cases)
was that the laboratory itself had a problem with the sample (e.g., test not run, sample ruined,
etc.). There were six complete observations for CD4 and viral load (VL), with both study
entry and study exit values reported. The standard deviations (SD) for CD4 and VL for these
pairs of observations were high, and given the low number of complete sets of laboratory
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measures, imputation analysis with an expectation-maximization (EM) algorithm was used to
replace missing values with plausible ones. Thus several values in the laboratory data were
imputed from the data that was available, based on estimates of likelihood. Given the low
number of participants, this imputation of laboratory values had to be done for statistical
power when analyzing that data. (P. Ricci, personal communication, September 20, 2009).
In analyzing for differences between the groups at the start of the study, imputation
analysis did not change results for sex, race/ethnicity, age, and ART duration in weeks.
Imputation analysis did change results for CD4, viral load count and viral load by log 10. The
groups were compared at study start, both before and after the imputation correction was
applied to the laboratory data. As shown in Table 4.4, the experimental and control groups
were equivalent at the beginning of the study.
Table 4.4
Group Comparison, Independent Samples Test: Post Imputation Analysis of Missing Values
Between Groups Sig.
(2-tailed)

Difference

Sex

.347

NS

Race/Ethnic

.313

NS

Age

.957

NS

ART Weeks

.838

NS

Starting CD4

.981

NS

Starting VL

.328

NS

Start Log10VL

.517

NS

Attribute

Note. Results are based on data set with imputation analysis, reflected in the clinical
measures for which there were missing data. ART: antiretroviral therapy. CD4: CD4
lymphocyte absolute count. VL: viral load. Log10VL: VL in log10. NS: not significant.
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Analysis of the Sample for Statistical Testing
Using Lenth’s (n.d.) Power Analysis for ANOVA Designs (Java applet) the following
numbers of participants are suggested for effects sizes of .50, .75, and 1.00: eight, four, and
two, for each group, respectively. Lenth notes that this applet is limited in its ability to
calculate samples sizes for multiple-measure designs. This limitation was addressed by taking
each measurement interval as a ―level‖ of measurement in the factor table, the number of
participants using Lenth’s applet describes eight levels in all. Hence for the number of
subjects in this study an effect size of .1.00 size was required to achieve a power of .80. As
was noted in Chapter Three, the study’s power analysis was originally based on a clinically
significant change of 20mm on symptom VAS scores, and on 30 participants completing the
protocol. Of the 33 participants originally enrolled in the study, only 18 completed the study.
Enrollment was halted due to a lack of additional eligible patients. Some pairs of laboratory
data were missing. Imputation was performed to create a data set that would respond to
analyses. The final data set did not fully meet criteria for parametric testing. There was no
random sampling, and values for skewness and kurtosis exceeded suggested limits. The
planned comparison for this study was based on parametric testing. For parametric testing to
be valid there are several criteria that should be met. The data must be normally distributed,
display homogeneity of variance, and be independent (Field, 2009). Frequency analysis was
performed on all of the variables in the sample including computation of skewness and
kurtosis. To summarize the results of this analysis, mean skewness and mean kurtosis are
reported in Table 4.5 for each of the four measurement points for the symptom scores
measured by a VAS. Values of skewness and kurtosis close to zero suggest more normal
distribution of scores. In smaller samples, values of skewness and kurtosis were converted to
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z-scores; those not exceeding a SD of 1.96 generally conformed to normality. Note that in
this sample, z-scores for kurtosis generally exceeded 1.96; however, in a sample this small,
even values that somewhat exceed 1.96 (2.0 - 2.5) do not necessarily stamp the sample as
non-normal (Field, 2009).
Table 4.5
Symptom Scores: Mean Skewness and Kurtosis
Average z -score
Skewness

SD

Average z -score
Kurtosis

SD

-0.03

1.69

-0.40

2.11

0.14

1.89

-0.39

2.35

-0.09

2.29

0.27

2.43

-0.28

1.78

-0.10

2.39

Symptom
measures T1
Symptom
measures T2
Symptom
measures T3
Symptom
measures T4

Note. SD: standard deviation; T1: time 1, at study entry; T2: time 2, measurement at 1 month,
or just prior to the first with the behavioral interventionist; T3: time 3, at 2 months, or just
prior to the second visit with the behavioral interventionist; T4, time 4, at 3 months and study
completion
Regarding the assumptions of parametric testing, it can be said that the groups were
independent, that some variances between the groups were not equivalent (sex, race/ethnicity,
ART duration, starting VL count), and that the distribution of symptom measurement scores
did not achieve normality.
Hypothesis Testing
There were three hypotheses:
1. Participants who received the cognitive-behavioral therapy (CBT) intervention would
report a reduction in side effects, compared to participants who only received the standard
of care (SOC).
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2. Participants who received the CBT intervention would show a difference in adherence
compared to those who only received the SOC.
3. Participants who received the CBT intervention would show a difference in CD4 and
VL compared to those who only received the SOC.
The first hypothesis was analyzed in two parts. First, side effects data from the third
(T3) and fourth (T4) measurements of nausea, pain, anxiety and fatigue are reported. Second,
general health data from the third (T3) and fourth (T4) measurements are reported and
examined in correlation with side effects. The symptom variables are described by the terms
used on the visual analogue scales for symptom measurements. As in Table 3.3, variables are
described in terms of the dimension of the symptom, e.g., ―usual nausea‖ or ―worst pain.‖
When discussing symptoms as general concepts, terms like ―nausea‖ and ―pain‖ are used.
Hypothesis One: Side Effects. The null hypothesis assumed that there would be no
differences between the groups with respect to side effect symptoms. For this study, the null
hypothesis was rejected in favor of the alternate hypothesis. The first hypothesis assumed that
participants who received the CBT intervention would report a reduction in side effects,
compared to participants who only received the SOC. Parametric testing was planned, but
was rejected at this stage because the data did not meet criteria for parametric testing. MannWhitney U and Wilcoxon rank sum testing were performed to determine between-group
differences on both the VAS symptom data and the SF-36 data for T3 and T4. The results
appear in Tables 4.6 and 4.7. Analysis of the means between groups did not show radical
differences between symptom scores before and after imputation analysis was performed.
Tables 4.6 and 4.7 display the results of the Mann-Whitney U exact test. One-tailed
testing for significance was used. All of these results demonstrated moderate effect sizes
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ranging from .41 to .52. Usual fatigue scores in the experimental group (Median [Mdn] =
42.00) were significantly lower than in the control group (Mdn = 60.00) at T3, U = 12.50, z =
-2.01, r = -.47, p < .05). Worst fatigue scores in the experimental group (Mdn = 59.00) were
significantly lower than in the control group at T3 (Mdn = 73.00), U = 15.50, z = -1.16, r = .40, p < .05). No significant differences between the groups resulted at T1 and T2.
Duration of nausea scores in the experimental group (Mdn = 17.00) were significantly
lower than in the control group (Mdn = 36.00) at T4, U = 18.00, z = -1.73, r = -.41, p < .05.
Imputed means and variances are not radically different from true means and variances.
Thus, the analysis changed little with imputation. Usual nausea scores in the experimental
group (Mdn = 11.95) were significantly lower than in the control group (Mdn = 32.00) at T4,
U = 21.00, z = -1.72, r = -.41, p < .05) only when the data were analyzed after imputation.
There was trend toward lower usual nausea scores in the experimental group (p = .08) when
the raw data were analyzed. The results of both analyses are shown in Tables 4.6 and 4.7
Hypothesis One: General Health. The SF-36 was used to look at general health measures
that could be affected by symptoms. For example, if nausea were a problem, it is reasonable
to expect that various health domains such as vitality, social role and others could be affected.
Moreover, the SF-36 measures domains, such as Bodily Pain that corresponds to pain as
measured by VAS. There were no significant differences between the experimental and
control groups.
To summarize, the experimental group reported significantly lower scores for nausea
and fatigue over the course of their involvement with the study after having been exposed to
the treatment intervention compared to the control group that received only the SOC.
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Table 4.6
Test of Hypothesis 1: Differences Between Groups at T3 and T4 Before Imputation

Time 3:
2 months

Time 4:
3 months

Mann-Whitney
U

Z

Exact Sig.
Point
Effect size
(1-tailed) Probability
(r)

Usual Nausea

28.000

-.374

.367

.017

Worst Nausea

24.000

-.801

.223

.012

Duration Nausea

23.500

-.854

.209

.015

Usual Pain

20.000

-1.217

.126

.021

Worst Pain

18.500

-1.377

.091

.009

Duration Pain

26.000

-.584

.293

.016

Usual Anxiety

30.500

-.106

.470

.022

Worst Anxiety

30.000

-.159

.459

.041

Duration Anxiety

31.000

-.053

.500

.041

Usual Fatigue

12.500

-2.013

.022*

.003

-.47

Worst Fatigue

15.500

-1.695

.047*

.005

-.40

Duration Fatigue

17.500

-1.485

.075

.008

Usual Nausea

21.000

-1.444

.080**

.007

Worst Nausea

28.000

-.771

.233

.015

Duration Nausea

18.000

-1.733

.043*

.005

Usual Pain

30.500

-.530

.313

.020

Worst Pain

35.000

-.096

.472

.019

Duration Pain

29.000

-.674

.263

.015

Usual Anxiety

31.000

-.481

.336

.034

Worst Anxiety

24.000

-1.155

.138

.020

Duration Anxiety

25.000

-1.060

.155

.011

Usual Fatigue

29.500

-.626

.279

.017

Worst Fatigue

28.500

-.723

.247

.014

Duration Fatigue

33.000

-.289

.398

.018

-.41

Note: * < or =.05 level of statistical significance. **Trend toward significance at .05 level. Z
= z-score for calculation of effect sizes. Only effect sizes for significant results have been
calculated.
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Table 4.7
Test of Hypothesis 1: Differences between Groups at T3 and T4 After Imputation

Time 3:
2 months

Time 4:
3 months

Usual Nausea

Mann-Whitney
U

Z

Exact Sig.
Point
Effect size
(1-tailed) Probability
(r )

39.00

-0.133

.456

.016

Worst Nausea

35.00

-0.489

.324

.015

Duration Nausea

35.50

-0.444

.340

.016

Usual Pain

28.00

-1.104

.149

.020

Worst Pain

22.50

-1.590

.060

.006

Duration Pain

35.00

-0.487

.323

.012

Usual Anxiety

38.50

-0.177

.441

.019

Worst Anxiety

37.00

-0.309

.398

.033

Duration Anxiety

40.00

-0.044

.500

.034

Usual Fatigue

15.50

-2.209

.013*

.001

-0.52

Worst Fatigue

18.50

-1.944

.026*

.002

-0.46

Duration Fatigue

25.50

-1.327

.099

.008

21.00

-1.723

.045*

.005

Worst Nausea

28.00

-1.105

.143

.010

Duration Nausea

18.00

-1.988

.024*

.003

Usual Pain

30.50

-0.883

.200

.013

Worst Pain

40.00

-0.044

.492

.017

Duration Pain

29.00

-1.017

.164

.011

Usual Anxiety

37.00

-0.309

.398

.033

Worst Anxiety

29.00

-1.015

.170

.021

Duration Anxiety

29.00

-1.017

.164

.011

Usual Fatigue

35.50

-0.442

.342

.017

Usual Nausea

-0.41
-0.47

Worst Fatigue

.013
Note: * < or =.05 level of statistical 31.50
significance.-0.796
Z = z-score.225
for calculation
of effect sizes.
Duration Fatigue

40.00

-0.044

.491

.017

Note: * < or =.05 level of statistical significance. **Trend toward significance at .05 level. Z
= z-score for calculation of effect sizes. Only effect sizes for significant results have been
calculated.
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Hypothesis Two. The second hypothesis predicted that participants who received the CBT
intervention would show a difference in adherence compared to those who only received the
SOC. The direction of such a difference was undetermined. Adherence was measured by a
VAS (Giordano, et al., 2004) and by a three-day recall instrument (Chesney, et al., 2000). At
three of the four measurement intervals, both measures were highly correlated. The data were
non-normal, with both the VAS adherence scores and the 3-day recall scores skewed sharply
to the right. Skewness changed little from when the data were examined in their raw state,
and when the data were transformed using the sum of squares and natural logs. Participants
were on ART an average of 200 weeks (SD 160.5) and had adherence rates approaching
100%. Adherence was high even at the study entry with mean adherence by the VAS of 93.4
(SD 10.86, range 70-100) and a 3-day recall of .89 (SD .17, range .67-1.00). Moreover,
Levene’s tests of variances were not homogenous for means (necessary for parametric
testing) (p <.05) but were homogenous for medians (p > .05) (either case is acceptable for
non-parametric testing). Two-tailed tests of significance were used for this analysis.
Between-group differences were non-significant and adherence rates were high for both the
experimental and control groups during the course of the study. The null hypothesis was
accepted.
Hypothesis Three. Participants who received the CBT intervention were expected to show a
difference in CD4 and VL compared to those who only received the SOC. The direction of
change was not hypothesized. The null hypothesis stated that there would be no difference
between the groups with respect to CD4 and VL. For CD4 there were six complete
observations for pre and post with the following means and SDs. Earlier it was noted that due
to the paucity of laboratory data imputation analysis was used to generate plausible pairs of
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Table 4.8
Correlations Between 3-day Recall and VAS for Adherence
Measurement
Interval
Study Start
Time 1

3DR – VAS
r

Significance

.81

p < .01

1 month
Time 2

.57

p < .05

2 months
Time 3

.98

p < .01

Study Exit
Time 4

.84

p < .01

Notes: 3DR: 3-day recall; VAS: visual analogue scale.

Figure 4.2 Weeks on ART at Study Entry, by Participant Number

Notes: ART: antiretroviral therapy. Actual values in weeks displayed in boxes.
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Table 4.9
Participant-estimated Adherence by VAS, Non-parametric Testing, Group Differences
Adherence
VAS
T1

Adherence
VAS
T2

Adherence
VAS
T3

1.395

2.138

.549

3.22000

1

1

1

100

Chi-Square
df

Adherence
VAS
T4

Asymp. Sig.
.237
.144
.459
.07300
Notes: Kruskal Wallis test, grouping variable by assignment. Asymp. Sig.:Asymptotic
significance.
CD4 counts and viral loads. During preliminary analysis of the data the extent of missing
data in this particular variable was observed, resulting in use of EM algorithm imputation to
continue the analysis. One case with missing data for both CD4 and viral load in the
experimental group was excluded. The imputed means and standard deviations were lower
but the patterns of means were the same.
Table 4.10
Descriptive Statistics of Raw Laboratory Data

Starting
CD4

N

Range

13

121 1362

Start
Log10VL 13

1.7

Ending
CD4

148 9999

18

Ending
Log10VL 18

.0

2.2

2.6

Mean

SD

Variance

Skew

Kurtosis

544.23

352.24

124069.53

1.14

1.14

1.92

0.11

0.01

0.26

3.29

2094.17 3647.37 13303302.74

1.93

1.99

-0.86

-0.98

1.41

0.92

Note: CD4: CD4 count, VL: viral load.
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Table 4.11
Descriptive Statistics: CD4 Means Compared Before and After Imputation
Mean

Standard
Deviation

N

Control

524.33

223.031

6

Experiment

600.17

484.194

6

Total

562.25

361.585

12

Control

519.00

175.442

6

Experiment

579.50

424.900

6

Total

549.25

311.533

12

Control

437.81

230.109

9

Imputation

Experiment

585.34

410.532

8

Analysis

Total

507.23

325.532

17

Control

446.37

181.799

9

Experiment

565.56

360.212

8

Total

502.46

277.584

17

Assignment
Before
Imputation

Starting CD4

Analysis
Ending CD4

After

Starting CD4

Ending CD4

A post hoc power analysis indicated (Keppel, 1991)(Keppel, 1991)(Keppel,
1991)(Keppel, 1991)(Keppel, 1991)(Keppel, 1991)(Keppel, 1991)that 54 participants in each
group would have been needed to show the interaction between viral load by group, assuming
no participant left the study. (P. Ricci, personal communication, May 28, 2010).
Consequently hypothesis three could not be analyzed. The null hypothesis could be neither
accepted nor rejected.
Confounding variables. Two other variables needed to be considered in the context of sideeffect symptom control in this study; the first was to account for the use of side effectreducing medication (SERM). The second confounding variable was how often experimental
group participants practiced the CBT techniques taught to them during the intervention visits,
progressive muscle relaxation therapy (PMRT), and guided imagery (GI) outside of the
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Table 4.12
Descriptive Statistics: Viral Load Means Compared Before and After Imputation
Assignment
Before
Imputation
Analysis

After
Imputation
Analysis

74.00

.000

7

Experiment

89.33

36.779

6

Total

81.08

25.038

13

Ending VL
Absolute
Count

Control

128.71

128.239

7

Experiment

79.17

28.046

6

Total

105.85

95.976

13

Starting VL
Absolute
Count

Control

78.08

9.221

9

Experiment

86.18

31.747

8

Total

81.90

61.34

17

Ending VL
Absolute
Count

Control

118.13

113.086

9

-2.54

225.247

8

22.379

180.128

17

Mean

Standard
Deviation

N

Control

1.900

.0000

7

Experiment

1.933

.1690

6

Total

1.915

.1104

13

Control

1.987

.3364

7

Experiment

1.898

.1423

6

Total

1.946

.2591

13

Control

1.922

.0541

9

Experiment

1.927

.1434

8

Total

1.924

.1023

17

Control

1.965

.2948

9

Experiment

1.713

.5168

8

Starting VL
Log10
Ending VL
Log10

Imputation

N

Control

Analysis

After

Standard
Deviation

Starting VL
Absolute
Count

Experiment
Total
Assignment

Before
Imputation

Mean

Starting VL
Log10

Analysis
Ending VL
Log10

Total
1.847
.4208
Notes: VL = viral load (serum viral RNA by branched chain DNA assay).
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17

intervention visits. Statistical testing was performed in order to analyze whether or not either
of these two confounders affected the results.
The use of SERM was recorded in ―checklist‖ diaries over each of the three months
that each participant was in the study. The use of SERM for both groups throughout the study
is shown in Figure 4.4. There were no statistically significant differences in SERM use
between the groups during the study.
Multivariate testing was used to examine the relationships of each type of SERM
(e.g., for nausea) against its effect on the relevant symptom, and whether that affected those
differences. The main focus of this testing was on nausea, because there was significantly
less nausea reported in the experimental group. Although there was also significant reduction
in fatigue in the experimental group, no data were collected on SERM for fatigue, because
there is no approved medication for fatigue. Therefore no testing for confounding effects for
SERM and fatigue was performed.
Practice of CBT Techniques. Multivariate analysis, again, showed no significance for
multivariate, within-subject effects, or within-subject contrasts. The data file was split to
exclude controls (which did not practice CBT) and bivariate analysis was performed on daily
practice against each of the 12 symptom variables. At T3, practice frequency was
significantly correlated with symptoms scores for usual nausea, duration of nausea, and usual
pain (Table 4.26). No other significant correlations were found. Practice per day of the CBT
techniques ranged from none (zero) to approximately nine times per week (1.29); two
different participants each were missing data for each of the measurements.
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Figure 4.3 SERM Use by Participants During the Study

Note: Bars display means and are grouped by measurement interval. 2 = during
participants’ first month in the study. 3 = during second month. 4 = from end of
second month to study exit.
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Table 4.13
Correlations Between Average Daily Practice and VAS Symptom Scores
Time 3
r
*

Time 4

Sig.
.03

r
.18

Sig.
.66

Nausea Usual

.79

Nausea Worst

.66

.11

.54

.17

Nausea Duration

.90**

.01

.35

.39

Pain Usual

.77*

.04

.33

.42

Pain Worst

.69

.09

.33

.42

Pain Duration

.50

.25

.00

1.00

Anxiety Usual

-.02

.97

.56

.15

Anxiety Worst

-.23

.62

.44

.28

Anxiety Duration

.05

.91

-.07

.87

Fatigue Usual

.40

.38

.07

.87

Fatigue Worst

.15

.75

.24

.57

.36
.43
-.23
.59
Fatigue Duration
Notes. *. Correlation is significant at the 0.05 level (2-tailed). **. Correlation is significant at
the 0.01 level (2-tailed). Positive correlations equate with symptoms increase with frequency
of practice. Negative correlations equate with decreasing symptoms with increasing practice.
Sig: significant.

Summary of Data Analysis
The sample was analyzed and found to be predominantly composed of white males.
Mean time on ART was 200 weeks. Random assignment did produce otherwise equivalent
groups with no significant differences in symptom scores, SF-36 scores, adherence, or
clinical measures at study entry.
Hypothesis testing was conducted using Mann-Whitney U. The experimental group
reported significantly lower mean symptom scores on nausea and fatigue. In the first case, the
null hypothesis asserted that there would be no difference between the experimental and
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control groups in symptom scores. The null hypothesis was rejected. The first hypothesis,
that participants in the experimental group would have fewer side effects, as evidenced by
lower symptom scores, was accepted.
In the second case, the null hypothesis asserted that there would be no difference in
adherence between the experimental and control groups at the close of the study. No
differences were found and the null was accepted. Mean adherence in both groups throughout
the study exceeded 90%.
In the third case, the null hypotheses asserted that there would be no difference
between the experimental group and the control group on CD4 and VL. No significant
differences were found. The null hypothesis was accepted.
Two confounding variables were tested for their correlation with symptom scores,
practice frequency of PMRT and GI, and use of SERM. The mean daily practice frequency
was 1.29 times per day. Increasing practice frequency of PMRT and GI was associated with
increasing symptom scores for nausea. The mean use of SERM per day for any symptom was
<1 dose per day. No correlation of SERM use with symptom scores was found.
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Chapter 5
Discussion and Implications
This chapter discusses the results of the study in terms of the hypotheses that were
proposed, limitations of the study, and implications of the results for nursing practice. Both
the hypothesis testing and recruitment issues are then linked to theoretical discussion in
Chapter 1.
Discussion of the Results
Hypothesis One. It was expected that HIV/AIDS patients would experience
improvements in subjective symptom complaints related to ART following CBT intervention
over time, similar to oncology patients who had received similar CBT interventions in other
studies (Loscalzo, 1996; Redd, et al., 2001) The first hypothesis proposed that participants in
the experimental group would report lower side effect symptom scores compared to those in
the control group. Participants who received the CBT intervention reported significantly less
nausea and fatigue than those who did not receive the intervention.
Higher levels of nausea were correlated with increasing frequency of practice of the
CBT techniques taught to participants, progressive muscle relaxation therapy (PMRT) and
guided imagery (GI) The positive correlation suggests that practice of CBT was associated
with increased symptoms at one point during the study. This was an unexpected and
paradoxical finding. Negative correlations would be expected if practice lowered symptom
scores. No other symptom scores were positively correlated with practice in this way. Such
an association is not consistent with the findings in other studies of CBT in anticipatory
nausea and vomiting (Burish, et al., 1987; Burish & Jenkins, 1992; Burish & Lyles, 1979;
Burish & Lyles, 1981; Burish & Tope, 1992; Carey & Burish, 1987; Carey & Burish, 1988;
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Morrow, et al., 1992; Mundy, et al., 2003; Redd, et al., 2001). However Zachariae et al.
(2007) note that autonomic sensitivity can make nausea worse when it is part of a conditioned
response. This suggests that thinking about nausea may make it worse, for some people. In
ART indefinite therapy that is generally less intensely emetogenic is the rule. Indeed, in this
study, levels of nausea ranged from about 20 to less than 45 on the VAS for all aspects of
nausea that were measured. However, standard deviations ranged from approximately 20-34,
which means that nausea was relatively modest in many participants, and was intense,
frequent or was of lengthy duration in a only few of the participants. It is thus difficult to link
the results of this study to that in oncology, given that in studies of CBT and oncology
(Arakawa, 1995, 1997; Burish & Lyles, 1979) there was much more focus on nausea. This
would be interesting to study further.
Hypothesis Two. It was hypothesized that the CBT intervention could have an effect
on adherence to medications over time. The null hypothesis was accepted because no
statistically significant differences between the groups were found. The sample results were
examined across the duration of the study, as well as between groups.
The adherence VAS and 3-day recall were significantly correlated with each other,
and thus reinforced each test’s validity and reliability. What was striking about the results
was not that the CBT intervention seemed to have no influence on adherence, but rather that
adherence was so high throughout the study. As was discussed in Chapter 2, adherence to the
antiretroviral regimen is considered a cornerstone of effective disease management in
HIV/AIDS (Press, et al., 2002).
Although adherence is generally high initially, over the course of one to two years it
can drop to 67%--only 2/3 of patients are adherent to 95% of doses (Chesney, 2003;
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Mannheimer, et al., 2002). Mean duration of ART in the sample of participants in the present
CBT trial was about four years. Thus it would be expected that adherence would have
averaged what has been reported in those other studies. As was noted in the review,
adherence has been shown to be influenced by a variety of factors including depression
(Boarts, Sledjeski, Bogart, & Delahanty, 2006), patients’ ideas about their illness and its
treatment (Wilson, et al., 2002), active substance abuse (Mellins, Kang, Leu, Havens, &
Chesney, 2003; Tanney, Naar-King, Murphy, Parsons, & Janisse, 2010) and other life factors
such as stressful events in the home (Mellins, et al.). This study did not collect data on those
factors, so the extent of such factors in the sample is unknown. Data on socioeconomic status
were also not collected. One explanation for the finding of high reported adherence in both
groups throughout the study may be that patients who manage to take ART for longer than
two years are more likely to remain adherent. However, this is not replicated when compared
with large, longitudinal cohort studies that have shown adherence to decline from >90% to
80% over 4 years (Lazo et al., 2007) and to 51.8% at a mean duration of ART of 4.5 years.
There are several possible reasons that the participants in this study reported exceptional
adherence: selection bias, poor recollection of actual adherence, deliberate misreporting,
lessened drug toxicity with newer agents, or better ways to treat side effects. No significant
differences in adherence were found over time, and given the high levels reported in both
group, it is unlikely that the sample was large enough to detect any difference.
Hypothesis Three: It was hypothesized that the CBT intervention could have an
effect on laboratory measures, CD4 counts and VL. There were many missing data points,
and both the raw data, and data based on imputed values, were described. The means,
variance and standard deviations changed little as a result. However, owing to the wide
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variance and large standard deviations both before and after imputation analysis, as well as
the small sample size and low statistical power it was decided that there was insufficient data
from which to draw conclusions. Moreover, recent evidence calls into question the current
clinical approach that utilizes CD4 lymphocyte counts as an ―absolute‖ measure of immune
competence against opportunistic infection. Robustness of viral containment by CD8
lymphocytes, natural killer (NK) activity (Alter & Altfeld, 2009), CD4/CD8 ratio (Forbi &
Agwale, 2009), and expression of CD38 and the immunopathogenic factor programmed cell
death (PD-1) (Holm, Pettersen, & Kvale, 2008) may factor more significantly than CD4
counts alone, which themselves are subject to considerable variation due to factors other than
virus level alone (Amatya et al., 2004).
Limitations of the Study
Sample Size and Composition. While the strength of the study design was that it
tested the intervention against an untreated control group, the sample size was small.
Although the study was fully enrolled (n = 33), only slightly over half of the enrollees
completed the trial. The sample was overwhelmingly male. Females now make up some 26%
of the population with HIV/AIDS (CDC_MMWR, 2005), so the sample did not adequately
represent the sex distribution in the general population. The sample was also overwhelmingly
made up of white men. This tends to limit the clinical applicability to similar populations.
However, given the moderate effect size of CBT interventions in other studies and this one,
and the greater likelihood of type II error in smaller samples, the multiple statistically
significant individual comparisons in VAS scores found in favor of the intervention in this
study are remarkable, since multiple effects in favor of the experimental group’s nausea and
fatigue scores was observed despite the actual effect sizes (<1.00) observed in the sample.

98

Adherence. Interestingly, the participants in both the experimental group and the
control group had a very high adherence to ART. With respect to the second hypothesis, any
potential impact of CBT on adherence would have been difficult to improve upon simply
because of the already very high adherence reported in this study. Clinically significant
improvement in adherence was probably not possible, even if the CBT intervention was
found to have a statistically significant effect.
Variations in Laboratory Testing and Missing Laboratory Data. Most CD4
counts and viral loads were performed by the same medical center laboratory, but not all
were. This introduced a confounding variable in the analysis of that data.
Missing data. Much missing laboratory data led to using an algorithm to generate
imputed values for missing CD4 counts and viral loads. Several participants simply did not
have their laboratory tests done as requested by their medical providers. No data were
collected on why this was the case. The clinical staff suggested that despite their best efforts,
such missed testing is commonplace.
Premise of the Study and Issues in Recruitment of Participants
As was noted in Chapter 1, the impetus for this study developed from the clinical
experiences of the investigator while working with HIV/AIDS 1996-2002 and involved
patients who fared poorly on ART due to intense and intractable side effects. Furthermore, an
exhaustive review of the literature showed that little research had been done in attempting to
mitigate the side effects of ART in HIV/AIDS patients. This study was conducted to gain
further insight into the effects of CBT on adverse symptomatology and thus, fill this gap in
the literature. This study is a step toward filling that gap.
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The low rate of recruitment was reported in Chapter 4 from data that tracked each
participant’s progress through the study. However, no data were collected about why some
people chose not to participate. Limited data were collected on why people withdrew. Many
patients were potentially eligible for the study, as they were on ART. The clinic database,
updated at each patient visit, showed that approximately 90% of those patients eligible to be
on ART were prescribed ART (Personal communication, J. Zurlo, March 19, 2007). Little
had changed by the time the study commenced in September 2008, and about 90% of the
clinic’s population was on ART (Personal communication, D. Greenawalt, September 2,
2008). Those few patients in the infectious disease clinic who were not on medications, fell
into two general categories: 1) they were ineligible for treatment based on the guidelines for
VL and/or CD4 count (Panel_on_Antiretroviral_Guidelines_for_Adults_and_Adolescents,
2009); or, 2) were ineligible for ―other reasons,‖ including active substance abuse (Personal
communication, D. Greenawalt, September 2, 2008). Screening by clinic staff eliminated
many patients due to 1) lack of reports of side effect symptoms; 2) belief that the person
lived ―too far away‖ to participate; or, 3) that the patient ―would not be good‖ for the study.
This reduced the pool of patients for consideration of enrollment.
Admission to the study was offered to those patients who the staff had screened for
participation as noted above. Patients were not questioned about why they chose not to
participate, as this could be interpreted as coercion. One of the hallmarks of ethical research
is non-coercion (Polit & Beck, 2004), and the investigator wished to avoid putting patients
―on the spot‖ when they are already in the vulnerable position of having HIV/AIDS.
However, some patients volunteered their reasons for non-participation:


―I have too much going on right now.‖
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―I have transportation issues.‖



―I don’t think my problems are from the medicine.‖ (From personal communications
kept in author’s notes and not specifically attributed for anonymity, September 9,
2008 through June 10, 2009.)
Scheduling with the psychologist for the intervention was a major concern expressed

with respect to the first two reasons stated. For those participants who were scheduled and
completed the series of three visits with the psychologist expressed very positive statements
about the experience and the techniques they learned. Nevertheless, scheduling not only
appeared to interfere with keeping medical appointments (Personal communication, D.
Greenawalt, April 28, 2009), but appeared to have some bearing on whether patients felt they
had the time to be in the study.
The third statement concerning patients who felt their symptoms were not medication
related was discussed earlier. It was assumed that patients know the difference. However it is
possible that they did not always know what momentary complaints were related to: HIV, comorbidities, or side effects. In summary, in addition to the restrictive selection by the clinic
staff, low recruitment may be related to patients’ concern about scheduling and availability
for the intervention, as well as lower reported side effect symptoms than expected.
Theoretical Framework
The theoretical framework for this study was based on cognitive control of autonomic
responses which would lead to lessening of autonomic symptoms caused by patients’
experience with ART. In the first chapter, anxiety was discussed as being both a symptom
and an amplifier of the discomfort associated with other symptoms such as nausea/vomiting,
pain, and fatigue. The literature review discussed the success seen in reducing symptoms

101

associated with antineoplastic therapy in cancer treatment. It was reasonable to theorize that
such CBT-related symptom reductions would apply in ART as well. In this study the
significant effects of the CBT intervention on side effects symptoms are consistent with
previous research, although the sample composition suggests limits to generalization to all
HIV/AIDS patients on ART.
In this study, anxiety and pain were not significantly different between the groups. As
noted in Chapter One anxiety is itself a symptom, and it has been theorized that anxiety also
amplifies other symptoms, such as pain (Adams & Field, 2001; Adams, et al., 2006; Colloca
& Benedetti, 2007), nausea (Burish & Carey, 1986), and fatigue (McCann & Boore, 2000). It
was expected that the findings of any decreased symptom—and in this study nausea and
fatigue were decreased in the experimental group—would co-occur with findings of
decreased anxiety, but this was not observed. It is possible that small sample size led to an
inability to detect changes in anxiety. It is also possible that anxiety has variable effects on
other side effect symptoms, and that CBT may modify such symptoms without also
modifying anxiety, especially in participants whose anxiety was low and other symptoms
were high. The sample size was not large enough to detect such interactive effects. The
experimental group failed to benefit with reduced anxiety from the CBT intervention, and
this runs contrary to both the literature and the theory (Hunot, Churchill, Silva de Lima, &
Teixeira, 2007). They did, however, benefit from the intervention with respect to nausea and
fatigue which is concordant with the literature on CBT in oncology (Carey & Burish, 1988;
Morley, et al., 1999; Mundy, et al., 2003; Redd, et al., 2001).
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Suggestions for Further Research
The results of this study suggest that CBT can help highly medication-adherent, male
HIV/AIDS patients on ART experience less nausea and fatigue, after only three CBT
sessions that include progressive muscle relaxation therapy (PMRT) and guided imagery
(GI), techniques that can be practiced outside the clinic, as patients feel the need to do so. It
was noted in Chapter Two that to date, no study had been published that tested
individualized, brief-contact CBT as a means of reducing side effect symptoms from ART.
Studies of CBT in symptom management have tended to employ a larger number of
therapeutic encounters. This is the only study that employed such a small number of
therapeutic encounters. The results of this study suggest that further exploration of briefcontact CBT-type interventions for symptom reduction should be explored further.
A larger study could be employed to examine the effects of CBT on symptom
reduction in women as well as men, in patients who are less adherent to ART, and in a wider
array of socio-cultural/ethnic groups. Further, a larger study enrolling more participants
might detect similar positive effects with respect to pain and anxiety. It would be useful to
expand the planned analysis of a larger sample to explore how individual practice of CBT
techniques influences symptom intensity, frequency, and duration, since there was positive
correlation between CBT practice and nausea. Although significant, this correlation may have
been by chance, and a larger study, designed to better detect such relationships, could provide
further clarity.
The recruitment and dropout rates, as well as anecdotal reports from candidates for
and participants in this study suggest that designing a larger study to recruit patients living
with HIV/AIDS to further study the effects of CBT on symptoms might not be practical
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without expanding enrollment to include multiple sites. Despite having access to some 600+
patients, only 18 completed the study. Although it is possible enlarging the pool of potential
participants in a multi-center trial would improve sample size, it was also true that clinic staff
controlled who was enrolled. Antiretroviral therapy to treat HIV disease has been in
continuous development since the 1980s, and following the success of multi-class antiviral
therapy in the mid-1990s, regimens have been improved with corresponding decreases in side
effects (Panel_on_Antiretroviral_Guidelines_for_Adults_and_Adolescents, 2009). Since this
is the case, fewer patients may benefit from CBT employed for the purpose of reducing side
effect symptoms. It is also possible that such symptoms are more burdensome early in ART,
and this study was not designed to select for those individuals. A follow up study might target
only patients on a new regimen.
Implications for Nursing Practice
The findings of this study lend support to the idea that a brief series of CBT sessions
can help to reduce symptom discomfort, at least for nausea and fatigue in HIV/AIDS patients
taking ART. In this sample, medication therapy is of life long duration. In long term ART,
symptoms can continue indefinitely as well. Nevertheless and despite a limited array of
change, significant changes were observed in the small sample used in this study. Moreover,
the intervention itself displayed no evidence of harm. In general CBT carries a low risk of
adverse effects when the sessions are focused on reducing autonomic arousal and inducing
relaxation for beneficial effects (J. S. Beck, 1995). Thus, given even the modest findings in
this study and the relative safety of CBT as practiced in this study, it is reasonable for nurses
to consider CBT interventions for HIV/AIDS patients who suffer from nausea and/or fatigue
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as while on ART. The brevity of the contact with CBT in this study creates a framework for
in-clinic trainings by nurses familiar with CBT methods like those used in this study.
Conclusions
In this study CBT was delivered in a small dose of three visits by a behavioral
interventionist to HIV/AIDS patients with any of four functional symptoms associated with
ART including fatigue, pain, nausea and anxiety. In this small clinical trial, the experimental
group reported significantly lower scores, compared to the control group, over time for some
measures of fatigue and nausea, but not pain or anxiety. The study was limited by low
enrollment, in part due to the lack of symptoms reported by patients as newer ART drugs
have been developed and marketed. A high dropout rate occurred and may have been due to
several causes including the difficulty of scheduling time with the behavioral interventionist,
as well as medical visits, which were separate from the study visits. Even with this small
sample, the study’s results suggest that CBT has some benefit for treating fatigue, and nausea
in these patients. Cognitive-behavioral therapy, as the study intervention, had no effect on
the biological parameters of CD4, viral load, or adherence to therapy. However adherence for
this study sample was reported overall to be higher than has been reported in HIV/AIDS
literature. Interestingly, in this study CD4 and VL were not correlated, nor was adherence
correlated with CD4 or VL. Moreover, the majority of participants had VLs that were
―undetectable‖ with values below the cutoff of 75 copies of viral RNA per mL. Little else
could be done to improve upon adherence and virus levels in this sample. There may have
been unintentional bias in how clinic staff prescreened patients for enrollment, and may have
represented the bias of the clinic providers who identifying individuals who they ―thought‖
would be appropriate for the study. The results of this study provide more insight into the
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management of the symptoms associated with ART in HIV patients, and suggest that CBT
may be a useful clinical tool to help reduce side effects of ART, at least in some patients.
The results suggest that a larger study might be worthwhile. A follow up trial might
focus on those patients most likely to have symptoms, patients who begin new regimens. The
effects of individual practice of the CBT techniques used in this study by patients (having
been taught those techniques by a therapist) might be studied, since individual practice was
unexpectedly correlated with increasing nausea. The effects seen from the small dose of CBT
and the problems encountered with recruiting and scheduling for the separate intervention
suggest that bringing such an intervention into the clinic and parallel with medical treatment
could prove valuable. This could easily be incorporated into nursing practice. Non-drug
interventions that fit into care models of nursing and skill set offer an important avenue to
reducing patient symptoms and improving their quality of life. The findings from this study
offer evidence that simple CBT techniques are useful for achieving improvements in patient
comfort, and can serve as a starting point for a promising line of research.
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APPENDIX A
DEMOGRAPHIC DATA FORM

Medication
Side Effect Study
Demographic Data
Form

PARTICIPANT NUMBER
Initials – Birthdate – 2-digit sequence
number
DATA COLLECTOR
DATE

Instructions: circle or complete each item as it applies
1. Biologic sex
male [1]

endocrine transsexual process, FM [4]

female [2]

surgical transsexual process, MF [5]
surgical transsexual process, FM [6]

endocrine transsexual process, MF [3]

2. Racial/ethnic group
Caucasian [1]

Other Hispanic [6]

Caucasian Hispanic [2]

East Asian [7]

African American [3]

South Asian [8]

African [4]

Pacific Islander [9]

African Hispanic [5]
3. Understand/read/speak English?
yes [1]
no [2]
4. Age (number): ___________
[number]
5. Duration of ART weeks: ______________
[number]
6. Does candidate suffer from any of the following that are related to ART?
Nausea &/or vomiting [1]

Fatigue [3]

Pain [2]

Anxiety [4]
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APPENDIX B
MEASUREMENT INSTRUMENTS
Facsimiles of the instruments appear on the following pages.
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DUQUESNE UNIVERSITY

School of Nursing

600 FORBES AVENUE  PITTSBURGH, PA 15282

INSTRUCTIONS
We would like to know how you feel about a few ordinary things today. There are several
things listed on the following pages. Each thing is a symptom or a feeling you may
experience while on HIV medication. Each question asks you about how strong the feeling or
symptom is, or how long you have been experiencing it. With each question there is a line
that looks like this:
MOST

The LEAST or NONE
The bottom of the line is the lowest, or least amount. The top is the most, strongest, or worst
feeling.
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And each line will have words that describe your feelings about the thing, a rough number of
the thing (like a few or many), or how long it lasts. Like this example:
FOOD: how tasty was your last meal?

The best meal ever

The best meal ever

For each item, use the
red pen to make a
mark on the line that
most describes the
LEVEL of the thing or
how long it lasts. Like
this:

Not at all

Not at all

That’s all there is to it! Please turn to the next page and complete the items. If you have any
questions, feel free to ask the research associate for help.
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PARTICIPANT NUMBER
Medication
Side Effect Study
VAS Page 1

DATE OF COMPLETION
MEASUREMENT NUMBER
DATA COLLECTOR

These three questions are about NAUSEA, ―sickness in the stomach,‖ or ―queasiness‖
1. Mark the line
with the usual
amount of
nausea in the
last month

2. Mark the line
with the worst
amount of
nausea in the
last month

3. Mark the line
with the length of
time you typically
felt nausea in the
last month

The worst ever

The worst ever

All the time

None

None

None
Page Over
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These three questions are about PAIN of any sort

1. Mark the line
with the usual
amount of pain in
the last month

The worst ever

None

2. Mark the line
with the worst
amount of pain in
the last month

The worst ever

None

3. Mark the line
with the length of
time you typically
felt pain in the
last month

All the time

None
Next Page
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PARTICIPANT NUMBER
VAS Page 2

DATE OF COMPLETION
MEASUREMENT NUMBER
DATA COLLECTOR

These three questions are about ANXIETY, ―nervousness,‖ or ―worry‖

1. Mark the line
with the usual
amount of
anxiety in the last
month

2. Mark the line
with the worst
amount of
anxiety in the last
month

3. Mark the line
with the length of
time you typically
felt anxiety in the
last month

The worst ever

The worst ever

All the time

None

None

None
Page Over
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These three questions are about FATIGUE, ―tiredness,‖ or ―no energy‖

1. Mark the line
with the usual
amount of fatigue
in the last
month

2. Mark the line
with the worst
amount of fatigue
in the last
month

None

None

The worst ever

The worst ever

3. Mark the line
with the length of
time you typically
felt fatigue in the
last month

All the time

None
Go onto the next page
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Medication
Side Effect Study

PARTICIPANT
NUMBER
DIARY DATES

FROM

Practice Sessions
Diary

TO
SET ____ OF ____
DATA COLLECTOR
NUMBER
INSTRUCTIONS

Your packet contains a calendar and the research associate has marked the calendar with your
study starting date. During the study, each time you practice the methods in your
personalized recording, mark that on the day that you did so. For example if you practiced
once on Thursday, March 20th, Saturday March 22nd, and Wednesday, March 26th then you
would mark the calendar like this:
Sunday

Monday

Tuesday

Wednesda
y

Thursday

Friday

Saturday

16

17

18

19

20

21

22

Practice
23

24

25

26

27

Practice
28

29

Practice
That’s all there is to it! You may practice your recorded exercises as often as
you feel it is necessary to maintain your health. If you have any questions,
contact a research associate at (717) 948-6513.
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APPENDIX C
RECORDING SHEETS FOR THE USE OF SERM
Facsimiles of this instrument appear on the following pages.
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Medication
Side Effect Study
Medication Diary

PARTICIPANT
NUMBER
DIARY DATES

FROM
TO

SET ____ OF ____
DATA COLLECTOR
NUMBER
INSTRUCTIONS

This is a diary to help you let us know how many doses of medicine you have used
to reduce side effects. Just fill in the date you took the medicine. Go from top to
bottom in each column, and when you run out of space, start at the top of the next
column. If you take more than 1 dose on a given day, you can just make a
checkmark below that date. Like this:
Medicines for NAUSEA
There is a diary chart for
each type of side effect
medicine we need to
know about
Just write in the
date when you
take your first
dose that day
Then just make
a check mark if
you take any
more doses that
day

If you run out of room, we have included a blank diary for you to fill in as needed.

ere is a diary chart for
each type of side effect
medicine we need to
know about
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2

Protocol # 000-0000-XXX : PARTICIPANT
NUMBER
DIARY DATES

FROM

TO

DATA COLLECTOR NUMBER
Medicines For PAIN

Medicines For NAUSEA, ―sickness in the stomach‖ or queasiness
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3

Protocol # 000-0000-XXX : PARTICIPANT
NUMBER
DIARY DATES

FROM

TO

DATA COLLECTOR NUMBER
Medicines For ANXIETY or nervousness

If you need more pages, please contact a research associate. Thank you!

150

APPENDIX D
INFORMED CONSENT
A facsimile of this document appears on the following pages.
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APPENDIX E
CONFIDENTIALITY AGREEMENT

DUQUESNE UNIVERSITY
600 FORBES AVENUE  PITTSBURGH, PA 15282
CONFIDENTIALITY AGREEMENT FOR: Clinical Trial of CognitiveBehavioral Therapy to Reduce Antiretroviral Side Effects in HIV Patients,
Primary Investigator, R. Eric Doerfler, CRNP, PhD(c)
_____________________________________
Name of Team Member

_____________________________________
Role

By signing below I acknowledge that I will be working as a research team member, and that
representing such, I will have access to sensitive medical/health information about participants in this
study. Some of this information relates to the HIV status and mental health status of research study
participants. I understand that all health information is protected by the U.S. Health Insurance
Portability and Accountability Act of 1996 and applicable laws of the Commonwealth of
Pennsylvania concerning HIV status, mental health, and substance abuse.
I agree to maintain the confidentiality of records and to adhere to the protocols for the security of
paper and electronic data, included in the study proposal approved by the Duquesne University
Institutional Review Board and the Office of Research.
If I identify a health concern of or hazard for a participant I understand that I am to disclose my
concern to the primary investigator and the participant’s treating clinician and/or nurse.
This agreement remains in force after the conclusion of the study and will be kept on file with the
primary investigator in accordance with applicable privacy laws and regulations.
_____________________________________
Signature of Team Member

___________________
Date

______________________________
Witness

__________________
Date
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